Ebola virus infection

The right clinical information, right where it's needed
## Summary

- A severe, often fatal, zoonotic infection caused by a virus of the Filoviridae family (genus Ebolavirus).

- Human-to-human transmission occurs via contact with body fluids from infected patients. The incubation period after infection is 1 to 21 days (typically 5-12 days), and patients are not considered infectious until they develop symptoms.

- Initial stages of infection are non-specific, which makes the differential diagnosis broad; therefore, clinical suspicion of the infection with prompt isolation is very important in the context of a history of exposure.

- Management is centred around supportive care and infection control. The lack of any specific antiviral treatment or approved vaccine makes treatment difficult; however, several potential therapeutic agents are undergoing accelerated development, and clinical studies are either planned or ongoing.

- Case fatality rates range from 20% to 90%. Survivors often have prolonged ill health with significant disability.

- The risk of sexual transmission from male survivors may persist for at least 9 months.

- As there is a high likelihood of infected people travelling, all countries should have tested and practised protocols ready for screening and managing patients.
**Definition**

A severe, often fatal, zoonotic infection caused by infection by a virus of the Filoviridae family (genus *Ebolavirus*). There are currently 5 known species: *Zaire ebolavirus*, *Sudan ebolavirus*, *Tai Forest ebolavirus*, *Bundibugyo ebolavirus*, and *Reston ebolavirus*. The *Zaire ebolavirus* is responsible for the outbreak that started in West Africa in 2014, the largest outbreak since the virus was first discovered in 1976.

The virus is thought to be initially acquired from infected animals such as bats and non-human primates, but has potential for human-to-human transmission. Transmission occurs by close contact with body fluids of infected patients. The incubation period after infection is 1 to 21 days (typically 5-12 days) in 95% of patients, with a mean of 11.4 days in the 2014 outbreak. Incubation periods may be shorter in children. Patients are not considered infectious until they develop symptoms. Human infection carries a high case fatality rate depending on the Ebola virus species and quality of supportive care available.

Ebola virus infection is part of the group of conditions known as viral haemorrhagic fevers, and was formerly known as Ebola haemorrhagic fever.

**Epidemiology**

The first cases of Ebola virus infection were reported in Zaire (now known as the Democratic Republic of the Congo) in 1976. There were 318 cases and 280 deaths, an 88% case fatality rate. Transmission in this outbreak was traced back to the use of contaminated needles in an outpatient clinic at Yambuku Mission Hospital. Since then, frequent outbreaks have occurred in Central and Western Africa.

The most common species of Ebola virus responsible for outbreaks is the *Zaire ebolavirus*, the second most common species being the *Sudan ebolavirus*.

The *Zaire ebolavirus* was responsible for the outbreak that started in West Africa in 2014. It was first reported in March 2014, and was the largest outbreak since the virus was first discovered in 1976. Genetic sequencing has shown that the virus isolated from infected patients in the 2014 outbreak is 97% similar to the virus that first emerged in 1976. Over 28,000 cases (confirmed, probable, and suspected) were reported in this outbreak, with over 11,000 deaths.

In May 2017, the World Health Organization (WHO) was informed of a cluster of undiagnosed illness and deaths in the north of the Democratic Republic of Congo. A sample from one patient tested positive for Ebola virus (the *Zaire ebolavirus* subtype). WHO declared the outbreak over on 2 July 2017, with a total of 8 probable or confirmed cases and 4 deaths.

The *Zaire ebolavirus* has reported a case fatality rate of 30% to 90% in previous outbreaks. Direct comparison of case fatality rates between different Ebola treatment centres and outbreaks should be interpreted with caution as many variables can introduce bias and skew even large cohort data. The case fatality rate during the 2014 outbreak was up to 64.3% in hospital admissions, falling to 31.5% in some treatment centres in West Africa, and around 20% in patients managed outside West Africa.
In contrast to this, the *Sudan ebolavirus* has a lower case fatality rate of 53% to 65% in previous outbreaks, with the largest outbreak occurring in 2000 in Uganda (425 cases). There has only been 1 outbreak of *Bundibugyo ebolavirus* in 2007 in western Uganda, and this outbreak had a case fatality rate of 25%.

WHO declares an outbreak over when a country has no new reported cases for 42 days (i.e., twice the maximum incubation period), provided that active surveillance is demonstrably in place and there is good diagnostic capacity.

Case counts:

- [World Health Organization (WHO): Democratic Republic of Congo external situation report]
- [Centers for Disease Control and Prevention (CDC): Ebola - 2017 Democratic Republic of the Congo, Bas Uélé District]

**Aetiology**

The Ebola virus is a member of the Filoviridae family (genus *Ebolavirus*; order: *Mononegavirales*). These viruses are elongated, filamentous structures of variable length.

The virus is thought to be initially acquired from exposure to body fluids or tissue from infected animals such as bats and non-human primates; however, the natural reservoir and mode of transmission to humans has not been confirmed. Laboratory testing of reservoir competence shows that successful infection is possible in bats and rodents, but not in plants or arthropods. Animal-to-human transmission may occur during hunting and consumption of the reservoir species or infected non-human primates. The local practice of eating bush meat or food contaminated with bat faeces (3 species of tree-roosting bats have been implicated as a reservoir) is also thought to contribute.
Ebola virus infection
Basics

Ebolavirus Ecology

**Enzootic Cycle**
New evidence strongly implicates bats as the reservoir hosts for ebolaviruses, though the means of local enzootic maintenance and transmission of the virus within bat populations remain unknown.

**Ebolaviruses:**
- Ebola virus (formerly Zaire virus)
- Sudan virus
- Tai Forest virus
- Bundibugyo virus
- Reston virus (non-human)

**Epizootic Cycle**
Epizootics caused by ebolaviruses appear sporadically, producing high mortality among non-human primates and dinkers and may precede human outbreaks. Epidemics caused by ebolaviruses produce acute disease among humans, with the exception of Reston virus which does not produce detectable disease in humans. Little is known about how the virus first passes to humans, triggering waves of human-to-human transmission, and an epidemic.

Following initial human infection through contact with an infected bat or other wild animal, human-to-human transmission often occurs.

**Centers for Disease Control and Prevention**

Human-to-human transmission occurs via contact with body fluids from infected patients. [34] In the early epidemics, the re-use of non-sterile injections was responsible for many healthcare-associated transmissions. [24] However, while this still remains a risk, most cases result from close physical contact or contact with body fluids (e.g., sweat, blood, faeces, vomit, saliva, genital secretions [including semen], and breast milk) of infected patients.

The level of virus in the blood increases during the course of illness and patients are most infectious in the later stages of the disease (i.e., during diarrhoea, vomiting, and haemorrhage). [35] Large amounts of virus can be found in the skin and, as sweat may also contain the virus, touching an infected patient may result in transmission. [36] Super-spreading events in the community are also increasingly recognised as a contributing factor: a funeral of a traditional healer in Sierra Leone in 2015 was linked to 300 cases. [37] In one study, it was found that super-spreaders were responsible for approximately 61% of infections in the 2014 outbreak. [38]

In a study to identify the rate of viral shedding in various body fluids, Ebola virus was isolated from saliva, breast milk, stool, tears, and semen up to 40 days after the onset of illness. [39] [40] [41] The virus can still be detected in semen more than 9 months after recovery from infection, possibly due to testicular tissue being an immunologically-protected site. [42] This means that sexual transmission may be possible long after the infection has resolved, [39] [40] [41] [43] [44] and such cases were confirmed during and following the 2014 outbreak. [45] [46] [47] Ebola virus has also been detected in vaginal fluid. [48] Viral shedding may continue
from urine and sweat. In one recovered patient in Germany, virus was detected in urine 14 days after it was not detected in serum, and in sweat for up to 19 days after it was not detected in serum.[36]

Infection via the inhalation route has been shown to be possible in non-human primates; however, there is no evidence for airborne transmission in humans.[15] [49] The possibility of opportunistic airborne transmission of the virus during forceful vomiting (similar to that seen with norovirus infection), and during aerosol-generating procedures associated with critical care interventions, should still be considered.

Outside the endemic areas, Ebola virus infection is rare and is usually an imported infection.[50] Travellers arriving from affected areas, as well as laboratory scientists and others working with potentially infected materials and animals, are at high risk.

[Centers for Disease Control and Prevention (CDC): Ebola transmission]

Pathophysiology

There have been major advances in elucidating the pathogenesis of Ebola virus infection; however, most of the studies have been performed in non-human primate and rodent models.[11] This is because of the difficulties in conducting human studies in poorly-resourced settings where these infections naturally occur.

The virus genome consists of a single 19 kb strand of negative-sense RNA with 7 viral genes that are transcribed by the viral RNA-dependent RNA polymerase present in the virion. The single strand of RNA is covered by helically-arranged viral nucleoproteins NP and VP30 that are linked by matrix proteins VP24 and VP4 to the lipid bilayer that coats the virion.[15] There was rapid mutation of the virus in the 2014 outbreak, raising concerns about its ability to evade host immune responses and evolve under pressure of novel therapies.[51] [52]

Tissue invasion occurs via infected fluid coming into contact with breaks in the mucosa or skin. This can occur with animal-to-human or human-to-human transmission. Monocytes, macrophages, and dendritic cells are the preferred replication sites for filoviruses on initial infection. Infected cells migrate to the regional lymph nodes, liver, and spleen, thereby disseminating the infection. Ebola virus has a wide cell tropism and is able to infect a variety of different cell types, but extensive viral replication occurs in lymphoid tissue, liver, and the spleen.[11] [15] [53] It also has the remarkable ability to modulate the expression of genes involved in the host immune response, causing lymphocyte apoptosis and attenuation of the protective effects of interferon.[54] [55] [56] [57] [58]

The host immune response is crucial and dictates the outcome of infection. Progression to the severe end of the disease spectrum occurs when the virus triggers expression of a host of pro-inflammatory cytokines, including: interferons; interleukins (IL) such as IL-2, IL-6, IL-8, and IL-10; interferon inducible protein; and tumour necrosis factor (TNF)-alpha.[11] [15] [59] This, in turn, causes endothelial activation and reduced vascular integrity, release of tissue factor (with associated onset of coagulopathy), and increased nitric oxide levels (with associated hypotension).[60] Infection leads to lymphocyte depletion through indirect apoptosis (since the virus does not replicate in lymphocytes), and neutrophil suppression via glycoprotein GP.[61] The most common cause of thrombocytopenia is platelet disappearance from damaged tissue or more generalised virus-induced disseminated intravascular coagulation, where coagulation factors are depleted.[62] Disseminated intravascular coagulation, along with acute hepatic impairment, predisposes the patient to bleeding complications. Other complications of severe disease include acute kidney injury, hepatitis, and pancreatitis.[15] Early antibody response, along with reduced lymphocyte depletion, is associated with effective viral clearance and survival.[63] Flow cytometry, which was used in a treatment...
Ebola virus infection

Basics

centre in Guinea during the 2014 outbreak, demonstrated that T-cell dysregulation (characterised by higher expression of CTLA-4 and PD-1 on CD4 and CD8 cells) was associated with death. This confirms earlier suggestions that an adequate, but controlled, immune response is key to survival.[64]

The development of shock is still not well understood. Multiple factors may contribute, including: bacterial sepsis, possibly through gut translocation of bacteria; a direct effect of the virus; disseminated intravascular coagulation; or haemorrhage.[59]

Classification

Virus taxonomy

The virus is a member of the Filoviridae family (genus *Ebolavirus*). Five distinct species of Ebola virus have been isolated from various epidemics, mainly in African countries, with the exception of the Reston virus that originated in the Philippines.[1] The latter is remarkable in that it has never caused symptomatic human disease. The other 4 species cause slightly different clinical syndromes of varying severity, and have a reported case fatality rate of 20% to 90% across different outbreaks.[5] *Zaire ebolavirus* and *Sudan ebolavirus* are especially known for their virulence; the other species are considered to be less virulent. The taxonomy of the virus continues to evolve, with new names emerging for variants of the virus.[6]

[Fig-1]

*Zaire ebolavirus*:

- First isolated in 1976 during an outbreak in northern Zaire (now known as the Democratic Republic of the Congo, or DRC).[7] Seems to be the most virulent of the 5 species and has the highest case fatality rate out of all species.[5] It is responsible for the outbreak that started in West Africa in 2014. A separate, limited outbreak in the DRC in 2014 was caused by a strain of *Zaire ebolavirus* distinct from the one that was circulating in West Africa.[8]

*Sudan ebolavirus*:

- First isolated in 1976 during an outbreak in southern Sudan. Causes an identical syndrome to *Zaire ebolavirus*; however, the case fatality rate is less.[5]

*Tai Forest ebolavirus* (formerly known as *Cote d’Ivoire ebolavirus*):

- Only 1 case has been documented in 1994 in a Swiss researcher who performed an autopsy on a dead chimpanzee in Tai National Park in Cote d’Ivoire.[9] She recovered from the febrile phase of the illness with no haemorrhagic complications.

*Bundibugyo ebolavirus*:

- Discovered in 2007 during a single outbreak in the Bundibugyo district of western Uganda. The isolated virus was identified as a distinct species, distantly related to *Tai Forest ebolavirus*.[10]

*Reston ebolavirus*:

- First isolated in Reston, Virginia, US in 1989 where it was found in Cynomolgus monkeys imported from the Philippines. Several workers exposed to infected animals were found to have positive

This PDF of the BMJ Best Practice topic is based on the web version that was last updated: Jul 31, 2017. BMJ Best Practice topics are regularly updated and the most recent version of the topics can be found on bestpractice.bmj.com. Use of this content is subject to our disclaimer. © BMJ Publishing Group Ltd 2018. All rights reserved.
Ebola virus infection

serology, but no clinical symptoms. Since then, the virus has also been isolated from pigs in the Philippines.[11] [12]

Other filoviral infections

The Filoviridae family of viruses includes: Ebola virus, Marburg virus, and Cuevavirus. Marburg virus is the only other member of this group known to cause human infection. It has been isolated from bats and causes a similar syndrome to Ebola virus infection. Several outbreaks have been reported, often related to animal exposure in mines or caves.[13]
Primary prevention

The following preventive measures are recommended for people in an area affected by an outbreak:

- Practise careful hygiene (e.g., wash hands with soap and water, alcohol-based hand sanitiser, or chlorine solution)
- Avoid contact with body fluids
- Do not handle items that have come into contact with an infected person's body fluids (e.g., clothes, medical equipment, needles)
- Avoid funeral or burial rituals that require handling of the body of someone who has died from confirmed or suspected Ebola virus infection
- Avoid contact with non-human primates and bats, including body fluids or raw meat prepared from these animals
- Avoid hospitals in West Africa in which infected patients are being treated (unless going there to work)
- Returning travellers (including healthcare workers) should follow local policies for surveillance and monitor their health for 21 days and seek medical attention if symptoms develop, especially fever.

Healthcare workers who may be exposed to infected patients should follow these steps:

- Wear protective clothing
- Practise proper infection control and sterilisation measures
- Isolate suspected patients from each other if possible, and confirmed patients from suspected patients
- Avoid direct contact with bodies of people who have died from confirmed or suspected infection. During epidemics, direct contact with any dead body should be avoided
- Notify health officials if you have direct contact with the body fluids of an infected patient.

[World Health Organization (WHO): aide-memoire for infection prevention and control in a health care facility]

[Centers for Disease Control and Prevention (CDC): infection control for viral haemorrhagic fevers in the African health care setting]

If infection is suspected based on initial screening, immediate isolation is warranted before any further work-up is carried out. This is crucial to reduce contact with other patients and healthcare workers while the patient is being investigated. Isolation measures should be continued until the patient has tested negative.[68]

The highest risk facing healthcare workers when looking after infected patients is inadvertently touching their own faces or neck under the face shield during patient care, and removing (doffing) personal protective equipment (PPE). Healthcare workers should understand the following basic principles of using PPE:[68]

[Fig-3]

- Donning: PPE must be donned correctly in proper order before entry into the patient care area. Since PPE cannot be modified while in the patient care area, caution should be taken to ensure it is as comfortable as possible before entering the area. No skin should be exposed. Donning activities must be directly observed by a trained observer, and a final check performed before entering the patient care area
- During patient care: PPE must remain in place and be worn correctly for the duration of exposure to potentially contaminated areas. PPE should not be adjusted during patient care. Healthcare workers should perform frequent disinfection of gloved hands using an alcohol-based hand rub or chlorine solution, particularly after handling body fluids. If there is a partial or total breach in PPE (e.g., gloves separate from sleeves leaving exposed skin, a tear develops in an outer glove, a needlestick) during patient care, the healthcare worker must move immediately to the doffing area to assess the exposure and implement the facility exposure plan, if indicated. The immediate action drills to take in the event of a high-risk exposure (needle stick injury and mucous membrane splash) should be clear to all
healthcare workers. After safe doffing, a rapid risk assessment and consideration of post-exposure prophylaxis (PEP) should be undertaken.[69]

- Doffing: removal of used PPE is a high-risk process that requires a structured procedure, a trained observer, and a designated area for removal to ensure protection. PPE must be removed slowly and deliberately in the correct sequence to reduce the possibility of self-contamination or other exposure. A stepwise process should be developed and used during training and daily practice.

The importance of a "buddy" when inside the patient care area and during donning and doffing, to ensure safe practice cannot be overstated, together with guidance from independent monitors if available. [Centers for Disease Control and Prevention (CDC): the buddy system]

The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) produce detailed guidance on PPE:

- [World Health Organization (WHO): personal protective equipment in the context of Filovirus disease outbreak response - rapid advice guideline]
- [World Health Organization (WHO): steps to put on personal protective equipment (PPE)]
- [World Health Organization (WHO): steps to remove personal protective equipment (PPE)]
- [Centers for Disease Control and Prevention (CDC): guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation (PUIs) for Ebola]

Vaccines:

- No vaccines have been licensed for use in humans.[70] rVSV-ZEBOV (also known as rVSV-ZEBOV-GP or V920) is a live attenuated vesicular stomatitis virus with 1 of its genes replaced by an Ebola virus gene. Phase I trials in the US, Germany, Gabon, Kenya, and Switzerland have confirmed the safety of this vaccine, although joint pain seems to be a common, self-limiting adverse effect.[71] [72] [73] The STRIVE (Sierra Leone Trial to Introduce a Vaccine against Ebola) trial is a combined phase II and III clinical trial to assess the safety and efficacy of rVSV-ZEBOV, and is currently being conducted in Sierra Leone. [Centers for Disease Control and Prevention (CDC): Sierra Leone trial to introduce a vaccine against Ebola (STRIVE) Q&A] An open-label, cluster-randomised, ring vaccination trial in which contacts of a suspected Ebola case were vaccinated with a single intramuscular dose of rVSV-ZEBOV was conducted in Guinea. Patients in the treatment arm received the vaccine immediately, while vaccination was delayed by 21 days in the control arm. The study found that rVSV-ZEBOV has a high protective efficacy. No patients who received the vaccine developed Ebola virus infection 10 days or more after randomisation in the immediate-treatment arm; however, cases occurred in unvaccinated patients in the comparison group.[74] The vaccine has been granted PRIME status by the European Medicines Agency and Breakthrough Therapy Designation by the FDA. Another vaccine candidate, which uses a prime-boost strategy to enhance immunogenicity and involves the use of 2 distinct viral vectors that are administered as different doses (Ad26-EBOV and MVA-EBOV), has undergone phase I clinical trials in the UK.[75] [76] A number of other vaccine candidates are in the development pipeline, including a recombinant protein vaccine undergoing phase I trials in Australia. ChAd3-ZEBOV is a chimpanzee-derived adenovirus vector with an Ebola virus gene inserted. Phase II and III trials are in progress.[77] [World Health Organization (WHO): Ebola vaccines, therapies, and diagnostics]

[World Health Organization (WHO): Ebola: infection prevention and control]
[Centers for Disease Control and Prevention (CDC): Ebola prevention]

Screening

Ebola virus infection is communicable mainly through close physical contact with infected patients. There is no evidence of a risk of infection before patients are symptomatic, but late diagnosis delays effective patient isolation, allowing for potential transmission of the infection among contacts. Screening and active case finding is, therefore, an essential management strategy to avoid or stop an epidemic.
Early diagnosis hinges on identifying patients who are at risk. Case definitions developed by the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) are based on the presence of a history of exposure, as well as clinical evidence of illness (e.g., fever, headache, myalgia). Within epidemic areas, history of exposure is less useful. Links to the case definitions by the WHO and CDC are below:

- [World Health Organization (WHO): case definition recommendations for Ebola or Marburg virus diseases]
- [Centers for Disease Control and Prevention (CDC): case definition for Ebola virus disease (EVD)]

Screening for these patients ensures the quick identification of potential cases that need immediate isolation and investigation. People who are asymptomatic and have epidemiological risk factors may need to be monitored (e.g., twice-daily temperature readings) for the duration of the incubation period depending on their risk of exposure. This is to ensure rapid recognition of symptoms followed by immediate isolation.

[World Health Organization (WHO): Ebola surveillance in countries with no reported cases of Ebola virus disease]

The WHO, CDC, and Public Health England have produced guidance for screening and caring for pregnant women.

[World Health Organization (WHO): Ebola virus disease in pregnancy: screening and management of Ebola cases, contacts and survivors]
[Centers for Disease Control and Prevention (CDC): guidance for screening and caring for pregnant women with Ebola virus disease for healthcare providers in US hospitals]

### Secondary prevention

Ebola virus infection is a notifiable disease.

If infection is suspected, the patient should be put in isolation and all healthcare workers in contact with the patient should wear personal protective equipment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) produce detailed guidance on PPE:

- [World Health Organization (WHO): personal protective equipment in the context of Filovirus disease outbreak response - rapid advice guideline]
- [Centers for Disease Control and Prevention (CDC): guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation (PUIs) for Ebola]

Contact tracing (e.g., family, friends, work colleagues) is essential. People who have been exposed to the Ebola virus within the last 21 days and who are asymptomatic need to be monitored for the duration of the incubation period in order to ensure rapid recognition of symptoms followed by immediate isolation. The WHO has produced guidance on contact tracing:

- [World Health Organization (WHO): implementation and management of contact tracing for Ebola virus disease]

Healthcare workers suspected of being infected should be isolated and treated the same as any other patient until a negative diagnosis is confirmed.[132] If exposure to body fluids from a patient with suspected infection has occurred, the person should immediately wash affected skin surfaces with soap and water and irrigate mucous membranes with copious amounts of water.
The patient’s home and any personal belongings that could have been contaminated (e.g., clothes, linens, eating utensils, medical material) should be appropriately disinfected (e.g., sprayed with 0.5% chlorine solution in epidemic areas) or disposed of (usually by incineration).

Safe burial practices are essential but are not always culturally accepted, and this continues to be a challenge.[65]

[World Health Organization (WHO): how to conduct safe and dignified burial of a patient who has died from suspected or confirmed Ebola virus disease]

Post-exposure prophylaxis:

- This is a rapidly changing field.[193] A useful framework that takes a stratified approach to exposure risk has been proposed. Those with the highest risk of infection (e.g., significant needlestick injury from a patient with a high viral load) would be prioritised for maximum therapy. This may include a combination of a suitable monoclonal antibody and antiviral drug. Moderate-risk exposures would warrant treatment with a suitable antiviral drug only.[69] Immediate post-exposure vaccination has also been used in lower-risk exposure settings. However, fever is a common adverse effect with immunisation, and this would then require full investigation for Ebola virus infection in a vaccine recipient who is already undergoing post-exposure fever surveillance.

[World Health Organization (WHO): Ebola: infection prevention and control]

[Centers for Disease Control and Prevention (CDC): Ebola prevention]
Case history

Case history #1

A 35-year-old man is brought to the Ebola screening centre in Liberia with a 3-day history of diarrhoea, vomiting, and fever. He reports that he attended the funeral of a nurse who died from Ebola virus infection 2 weeks ago. He developed dysphagia and hiccups 24 hours ago, but had been eating normally until then. He has no symptoms of bleeding. On examination, he is found to have mild conjunctival injection, a faint maculopapular rash over his trunk, mild epigastric tenderness, and hepatomegaly. His vital signs on admission are a temperature of 38.3°C, heart rate 100 bpm, blood pressure 115/62 mmHg, respiratory rate 25 breaths per minute, and oxygen saturation 99%.

Case history #2

A 37-year-old doctor who worked in an Ebola treatment centre in Sierra Leone returned to the UK 3 days ago. She presents with a fever of approximately 12 hours duration, headache, and myalgia. She reports sustaining a cut while opening a vial at the Ebola treatment centre 10 days ago. During her stay, she reports taking atovaquone/proguanil for malaria prophylaxis. There are no abnormal findings on examination except for several mosquito bites. Her vital signs are a temperature of 39.0°C, heart rate 110 bpm, blood pressure 120/75 mmHg, respiratory rate 25 breaths per minute, and oxygen saturation 99%.

Other presentations

People who eventually die from Ebola virus infection tend to develop clinical signs early on in the infection, with death (due to shock and multi-organ failure) typically occurring between days 6 and 16 of infection.[5] [14] [15] [16]

Bleeding manifestations (e.g., epistaxis, bleeding gums, haemoptysis, easy bruising, conjunctival bleeding, haematuria, oozing from injection or venipuncture sites) were present in 30% to 36% of infected patients in previous outbreaks;[12] [17] [18] however, they were only reported in 5% to 18% of patients in the 2014 outbreak.[3] [19] Massive bleeding is usually only observed in fatal cases, and typically occurs in the gastrointestinal tract (e.g., bloody diarrhoea, melaena).[17] [20] [21] [22] Internal bleeding may be missed if there are no external signs.

Other signs that indicate severe or advanced infection include hiccups, hypotension, tachycardia, hepatomegaly, splenomegaly, confusion, and seizures.

Up to half of patients develop a maculopapular rash, which may become purpuric or petechial in patients with coagulopathy.[17] [23]

Step-by-step diagnostic approach

Ebola virus infection is a notifiable disease. The case definition for Ebola virus infection is very broad and includes a long list of possible differential diagnoses.

The initial assessment of a patient with suspected Ebola virus infection hinges on 2 main factors:
• Epidemiological risk (e.g., living or working in, or travel to, endemic area in previous 21 days); and
• Presence or history of a fever in the past 24 hours.

**Isolation and personal protective equipment (PPE)**

Infection control risk should be assessed. Having determined that a patient may be infected, the physician needs to determine how infectious the patient is currently. For example, the absence of vomiting/diarrhoea reduces the risk; however, uncontrolled diarrhoea greatly increases the risk of transmission.

Identifying that a symptomatic patient may be at risk of infection mandates precautionary isolation procedures and use of PPE until the infection is either confirmed or excluded. It is extremely important to minimise the risk of transmission while working up the patient.[78] [79]

The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) produce detailed guidance on PPE:

- [World Health Organization (WHO): personal protective equipment in the context of Filovirus disease outbreak response - rapid advice guideline]
- [World Health Organization (WHO): steps to put on personal protective equipment (PPE)]
- [World Health Organization (WHO): steps to remove personal protective equipment (PPE)]
- [Centers for Disease Control and Prevention (CDC): guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation (PUIs) for Ebola]

The CDC and WHO also produce detailed guidance on infection control for healthcare workers in West Africa:

- [World Health Organization (WHO): infection prevention and control (IPC) guidance summary]
- [Centers for Disease Control and Prevention (CDC): international infection control for healthcare workers (non-US healthcare settings)]

**History**

A detailed history helps to clarify the level of risk for Ebola virus infection, as well as assess the possibility of other causes of an acute febrile syndrome.

People living or working in endemic areas (e.g., West Africa) are at high risk of infection. However, recent arrival from endemic areas is also an important risk factor.

Most patients with suspected infection in developed countries will be returning travellers and healthcare workers who have cared for patients during outbreaks. Therefore, a comprehensive travel history is extremely important. History of recent arrival from an endemic area is significant. Up-to-date knowledge of the geographical locations of active epidemics helps to clarify the patient’s epidemiological risk.

Apart from healthcare workers, other high-risk occupations include those where people work with primates or bats from endemic areas, or high-risk clinical samples.

As malaria is still the most common cause of febrile illness in returning travellers from West Africa, the presence of risk factors for acquiring malaria should be assessed (e.g., living/working in, or travelling to, endemic area; inadequate or absent chemoprophylaxis; not using insecticides or bed nets).[80] However,
Ebola virus infection

co-infection with malaria was seen in up to 5% of patients in West Africa during the 2014 outbreak, so the possibility of dual infection should be considered in all patients.[81]

**Exposure risk**

Contacts of infected patients (including healthcare workers and household contacts) are at risk of infection if the person was exposed to body fluids of the infected patient without appropriate protective equipment. The incubation period after infection is 1 to 21 days (typically 5-12 days) in 95% of patients,[2] [3] with a mean of 11.4 days in the 2014 outbreak.[3] Incubation periods may be shorter in children.[4] Brief interactions, such as walking by a person or moving through a hospital, do not constitute close contact.

Epidemiological risk factors are divided into high risk, some risk, low (but not zero) risk, and no identifiable risk categories.

[Centers for Disease Control and Prevention (CDC): epidemiologic risk factors to consider when evaluating a person for exposure to Ebola virus]

Contact is defined by the World Health Organization (WHO) as someone who has:[82]

- Slept in the same household as a patient
- Had direct physical contact with the patient during the illness or at the funeral
- Touched the patient's body fluids or clothes/bed linens during the illness
- Been breastfed by the patient (babies).

**Case definitions**

Case definitions are updated frequently and differ depending on the organisation. Links to the case definitions by the WHO and CDC are below:

- [World Health Organization (WHO): case definition recommendations for Ebola or Marburg virus diseases]
- [Centers for Disease Control and Prevention (CDC): case definition for Ebola virus disease (EVD)]

**Symptoms**

The incubation period after infection is 1 to 21 days (typically 5-12 days) in 95% of patients,[2] [3] with a mean of 11.4 days in the 2014 outbreak.[3] Incubation periods may be shorter in children.[4] Patients are not considered infectious until they develop symptoms.

The initial presentation is non-specific, which makes early clinical diagnosis difficult; however, typical symptoms include:[7]

- Fever
- Fatigue
- Nausea/vomiting
- Diarrhoea
- Headache
- Abdominal pain
- Myalgia
- Prostration
- Sore throat
Ebola virus infection

Diagnosis

- Unexplained bleeding or bruising.

The most common symptoms reported between the onset of symptoms and case detection in the 2014 outbreak included: fever (87.1% to 89%), fatigue (76.4%), loss of appetite (64.5%), vomiting (67.6%), diarrhoea (65.6%), headache (53.4%), abdominal pain (44.3%), and unexplained bleeding (18%).[3][22] Chest pain (10%), cough (7%), and sore throat (9%) have also been reported,[19] but direct involvement of the lungs has only rarely been reported.[83] Myalgia has also been reported (22%) and, in facilities that could measure this, raised creatine kinase was common (36% to 83%).[19][81][84][85]

Three phases of illness are typically recognised, starting with a few days of non-specific fever, headache, and myalgia, and followed by a gastrointestinal phase where diarrhoea, vomiting, abdominal symptoms, and dehydration are prominent.[53] In the second week, the patient may either recover, or deteriorate with a third phase of illness, which includes collapse, neurological manifestations, and bleeding. This phase is often fatal.[3]

Data from the 2014 outbreak indicate that children are relatively spared; however, this may be confounded by a high fatality rate before being registered as a case, or the bias of high rates in healthcare workers.[86] Children present with similar symptoms to adults; however, in previous outbreaks, younger children are reported to have more respiratory (e.g., cough, dyspnoea) and gastrointestinal symptoms, but less bleeding and neurological signs compared with adults.[87] Data were sparse for this patient group in the 2014 outbreak.[87][88] A paediatric cohort study in Sierra Leone described symptoms in 279 patients and found vomiting (60%), diarrhoea (45%), and conjunctivitis (26%) were common, while hiccups (5%) and bleeding (1%) were rare.[89] Anecdotally, children under 4 years of age initially present with more subtle symptoms before developing a fever, and are often diagnosed later in the course of illness.

**Physical examination**

A full physical examination should be undertaken with the aim of excluding a focus for sepsis while looking for signs of viral haemorrhagic fever (e.g., conjunctival injection, purpuric rash, or other signs of bleeding).

Vital signs should be taken:

- Fever ≥37.5°C: the presenting symptom in approximately 90% of patients,[3][22][90] its presence is enough to raise concern for infection in the appropriate epidemiological context. Wide variations in body temperature can be observed during the course of illness with normothermia or hypothermia occurring in the later stages of fatal infection.[17][18][87] Some patients may initially have a low-grade fever with no other symptoms, or alternatively the temperature may be near normal at first evaluation.[91] The temperature threshold for fever differs among countries and guidelines, and using a lower temperature threshold increases the sensitivity of finding cases.[90][92] Although fever is a major presenting symptom, a normal temperature at presentation is common. In a large cohort in Sierra Leone, <30% had a fever of ≥38°C at presentation, although a history of fever was reported by 89% of patients.[22]
- Blood pressure: hypotension is a feature of pre-terminal disease and shock. It is under-documented in field studies, owing to a lack of measuring equipment in endemic areas.[17] However, septic shock with vascular leakage and microcirculatory failure does not appear to be a dominant feature.
- Pulse rate: bradycardia may be present in the initial stages of illness; however, tachycardia may be seen in the later stages of fatal infections.[17]
• Respiratory rate: tachypnoea, along with tachycardia, correlates with a more severe or advanced infection, and is more likely to be respiratory compensation of a metabolic acidosis rather than respiratory involvement.[17] However, respiratory involvement has been described.[83]

Other findings may include:[17]

• Maculopapular rash: develops early in the course of illness in approximately 25% to 52% of patients,[17] although was much lower (1% to 5%) in the 2014 outbreak.[3] [19] [85] It is frequently described as non-pruritic, erythematous, and maculopapular. It may begin focally, then become diffuse, generalised, and confluent. Some have described it as morbilliform. It may become purpuric or petechial later on in the infection in patients with coagulopathy.[23] May be difficult to discern in dark-skinned patients.

• Bleeding: bleeding manifestations (e.g., epistaxis, bleeding gums, haemoptysis, easy bruising, conjunctival bleeding, haematuria, oozing from injection or venipuncture sites) were present in 30% to 36% of infected patients in previous outbreaks;[12] [17] [18] however, they were reported in only 5% to 18% of patients in the 2014 outbreak.[3] [19] [20] [21] [22] It is less common in children.[89]

• Hiccups: a sign of advanced infection, typically seen in the last 2 to 3 days of fatal infections. They are less common in children.[89]

• Hepatomegaly: tender hepatomegaly with the edge of the liver palpable below the rib cage has been reported, but is uncommon.

• Lymphadenopathy: enlarged lymph nodes have been reported, but are uncommon.

• Neurological signs: depressed consciousness, encephalopathy, and seizures are rare but their presence indicates advanced infection. Confusion was more common in the 2014 outbreak.[85]

Initial investigations

All specimens should be collected according to strict protocols. The WHO and CDC have published guidance on this:

• [World Health Organization (WHO): how to safely collect blood samples from persons suspected to be infected with highly infectious blood-borne pathogens]

• [Centers for Disease Control and Prevention (CDC): guidance for collection, transport and submission of specimens for Ebola virus testing]

• [Centers for Disease Control and Prevention (CDC): guidance for US laboratories for managing and testing routine clinical specimens when there is a concern about Ebola virus disease]

The main confirmatory test for Ebola virus infection is a positive reverse transcriptase-polymerase chain reaction (RT-PCR) for Ebola virus.[93] This test should be ordered in all patients with suspected Ebola infection while the patient is in isolation. It has the advantage of returning a result 24 to 48 hours before ELISA testing. Several different commercial PCR kits are available with varying sensitivity, specificity, and limits of detection.[94] In Western settings, the test may only be available in regional or national laboratories that have category 4 facilities.[11] In epidemic settings and some countries, category 4 laboratories are set up locally and results are available 4 hours after the sample has arrived. Viral RNA can be detected in the patient’s blood by RT-PCR from day 3 up to days 6 to 17 of symptom onset. A positive PCR result implies that the patient is potentially infective, particularly if he or she has active diarrhoea, vomiting, or bleeding. If negative, the test should be repeated within 48 hours since viral load is low and can be undetectable early in the course of the illness. Negative tests should be repeated to rule out a diagnosis if it is strongly suspected (or confirm resolution of infection).[93] Higher viral load correlates with adverse outcome and increased mortality.[20] [21] [22] [60] [81] [93] [95]
The choice of whether to test for Ebola virus infection depends on the patient’s history and their risk of infection according to the algorithm below.

1. **Patient who has resided in or travelled to a country with widespread Ebola transmission in the 21 days before onset of illness**
   - **Fever or other compatible Ebola symptoms**
     - e.g., headache, weakness, myalgia, vomiting, diarrhoea, abdominal pain, bleeding
   - **YES**
     - Isolate patient in single room with private bathroom
     - Implement standard, contact, and droplet precautions
     - Notify hospital infection Control Programme and other staff
     - Evaluate for risk of Ebola exposure
     - Report to health department immediately
   - **NO**
     - Report asymptomatic patients with low- or high-risk exposures in the past 21 days to the health department

2. **High-risk exposure**
   - e.g., contact with skin, blood, or body fluids of infected patient (dead or alive) without appropriate PPE
3. **Low-risk exposure**
   - e.g., household members of an Ebola patient or others who have had brief contact without appropriate PPE

**Testing indicated**

**Diagnosis**

Malaria is still the most common cause of fever in people who live/work in, or travellers who have returned from, an endemic area and should be ruled out.[96] Co-infection with malaria was seen in up to 5% of patients in West Africa during the 2014 outbreak, so the possibility of dual infection should be considered in all patients.[81] In the case of a positive rapid diagnostic test result for malaria, the infection should be treated while keeping in mind the patient’s risk for Ebola virus infection and the possibility of a dual infection. Ebola virus infection should be considered in a patient who does not respond to antimalarial therapy.

It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests for other suspected conditions if Ebola virus infection is suspected.

**Other investigations**

Traditionally, no other investigations outside of a malaria screen and RT-PCR were recommended due to the fear of putting laboratory workers at risk. However, it is now recognised that other investigations can be done safely according to recommended guidelines, as long as the laboratory is informed of the sample in advance, and the bloods are correctly packaged and retained at the end in case the RT-PCR is positive. Local protocols should be clear about safe transport of samples to the local and referral laboratories, and safe handling on receipt in the local laboratory.
The following investigations add valuable information to the work-up and help guide further management, and should be ordered if possible. If investigations are limited due to the geographical location or facilities available, the most important tests to order are renal function, serum electrolytes, and blood lactate (if available).

Renal function and serum electrolytes:

- Elevated serum creatinine or urea and abnormal electrolytes may indicate acute kidney injury. This may be seen at the end of the first week of infection. Hypokalaemia or hyperkalaemia, due to vomiting and diarrhoea or acute kidney injury, was seen in approximately 33% of cases in the 2014 outbreak. Hypocalcaemia has been associated with fatal infection. Haematuria and proteinuria may also be seen in severe disease. Oliguria that does not respond to fluid resuscitation is a poor prognostic sign.

Blood lactate:

- Elevated lactate is a marker of tissue hypoperfusion and is an indicator of shock. It is useful in acutely ill patients with signs of sepsis to identify the degree of systemic hypoperfusion and to guide fluid resuscitation. Elevated lactate was one indicator of gram-negative sepsis at day 15 in a patient treated in Germany.

ABG:

- Arterial or venous blood pH and bicarbonate are useful in acutely ill patients with signs of sepsis to identify the degree of systemic hypoperfusion and guide fluid resuscitation.

FBC:

- Decreasing platelet count and marked lymphopenia can be seen in the initial stages of infection; however, this is not diagnostic. This is often followed by neutrophil leukocytosis in the later stages of patients who eventually recover, along with normalisation of thrombocytopenia. Leukocytosis may persist and show immature forms. Patients with severe disease may show a progressive decline in platelet count as a manifestation of disseminated intravascular coagulation (DIC). Decreased haemoglobin levels were reported in 24% of patients in the 2014 outbreak, and have been associated with bleeding in previous outbreaks.

Coagulation studies:

- Prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT) is associated with more severe infection and bleeding manifestations such as DIC. Also, patients with fatal infections have been found to have D-dimer levels four-fold higher on days 6 to 8 of infection compared with patients who survive.

LFTs:

- Both ALT and AST are usually elevated; however, most studies show that AST rises out of proportion to ALT, and this is more suggestive of systemic tissue damage rather than hepatocellular injury. The AST:ALT ratio peaked at 15:1 on days 6 to 8 of infection in fatal cases when compared with non-fatal cases, which had a peak of 5:1. Bilirubin, GGT, and ALP are often slightly elevated. Highly elevated ALT with severe jaundice suggests an alternative diagnosis (e.g., viral hepatitis).
Serum amylase:

- Elevated levels have been reported in several studies and indicate the presence of pancreatitis, an indicator of severe infection.[17]

Blood cultures:

- Negative blood cultures are helpful as they rule out other non-viral infectious causes (e.g., sepsis, enteric fever). Gram-negative bacteraemia, presumably from gut translocation, was identified as a complication of the disease course in one patient who was repatriated to Germany.[36] However, a study in Sierra Leone where blood cultures were taken from patients on admission to an Ebola treatment centre found that only one of the 22 cultures was positive with a presumed contaminant.[100] Therefore, blood should be collected for culture at baseline and/or at the time of the onset of gastrointestinal symptoms or other clinical deterioration.

Antigen-capture enzyme-linked immunosorbent assay (ELISA) testing:

- A useful diagnostic test with high specificity; however, it is not universally available. It is most likely to give a positive result from day 3 until day 6 of infection, and can give widely variable results from days 7 to 16.[41] Can be used to confirm the diagnosis along with a positive RT-PCR result.

IgM and IgG antibodies:

- Useful in later stages of infection. IgM antibodies can appear in serum as early as day 2 post infection, but can give variable results up to day 9. They become negative between 30 and 168 days after symptom onset. An IgG response develops between day 6 and 18 and can persist for several years. A positive IgM or a rising IgG titre is strong evidence for recent Ebola virus infection.[41]

Chest x-ray

- Useful in patients with respiratory symptoms. Pulmonary infiltrates are not typical of infection and suggest an alternative (or comorbid) diagnosis. May be difficult to arrange in an isolation unit and should only be ordered judiciously to avoid contamination.[101]

### Rapid diagnostic tests

Rapid PCR testing for Ebola virus infection remains a major hurdle for effective, targeted isolation of affected patients. Current tests take an average of 4 hours to perform with a fully equipped level 3 or 4 biosafety laboratory close at hand, but results may take several days to arrive in remote areas. This means that, until they are confirmed negative, patients with febrile illnesses other than Ebola virus infection are confined to isolation and often unwittingly exposed to the virus. Rapid bedside tests can therefore make a very significant contribution to infection control in treatment centres.

[World Health Organization (WHO): interim guidance on the use of rapid Ebola antigen detection tests]

Several different technologies are being evaluated by WHO for use in field conditions. These include numerous RT-PCR-based assays that have been made simpler to use with a shorter turnaround time of <1 hour. The WHO has listed ReEBOV™ Antigen Rapid Test Kit for potential use; however, it currently only recommends its use in special situations. The alternatives are ELISA-based antigen-detection assays that could be quicker and simpler with the possible advantage of only needing a drop of blood. Their major disadvantage is a reduced sensitivity, particularly in the initial stages of illness.[102] [103]
Nanopore technology may allow rapid detection and sequencing in the presence of very low levels of virus, and can potentially be deployed using a pocket-sized detection kit.[104] [105] Rapid sequencing of Ebola virus using these new technologies during an outbreak could allow real-time understanding of viral dynamics.[106]

A GeneXpert® diagnostic tool has been developed and trialled in the field. The Xpert® Ebola is an automated cartridge-based system that requires minimal laboratory skill. An inactivated sample is placed into a single-use cartridge, which is then entered into the enclosed machine. Sample preparation, nucleic acid amplification and detection, and production of a result are automated processes minimising staff training requirements, risk of infection, and cross contamination.[107]

This is a rapidly evolving field and different kits are approved according to the country and settings in which they are to be deployed. Food and Drug Administration (FDA) and WHO recommendations are available:

- [World Health Organization (WHO): Ebola vaccines, therapies, and diagnostics]
- [Food and Drug Administration (FDA): 2014 Ebola virus emergency use authorizations]

[World Health Organization (WHO): clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker]

[Centers for Disease Control and Prevention (CDC): Ebola diagnosis]

[Public Health England: Ebola virus disease - clinical management and guidance]

### Risk factors

#### Strong

**Living or working in, or arrival from, endemic area in previous 21 days**

- People living or working in endemic areas (e.g., West Africa) are at high risk of infection. However, recent arrival from endemic areas is also a significant risk factor. Most patients with suspected infection in developed countries will be returning travellers and healthcare workers who have cared for patients during outbreaks.
- Up-to-date knowledge of the geographical locations of active epidemics helps to clarify the patient’s epidemiological risk.

**Contact with infected body fluids**

- Human-to-human transmission occurs via contact with body fluids (e.g., sweat, blood, faeces, vomit, saliva, genital secretions [including semen], and breast milk) from infected patients.[34] [39] Virus levels in these fluids are particularly high in more severe or advanced infection. The incubation period after infection is 1 to 21 days (typically 5-12 days) in 95% of patients,[2] [3] with a mean of 11.4 days in the 2014 outbreak.[3] Incubation periods may be shorter in children.[4]
- Contacts of infected patients (including healthcare workers and household contacts) are at risk of infection if the person was exposed to body fluids of the infected patient without appropriate protective equipment. Household contacts of infected patients are at a higher risk of infection if there is active diarrhoea, vomiting, or bleeding.[34]
• Epidemiological risk factors are divided into the following categories: high risk, some risk, low (but not zero) risk, and no identifiable risk. [Centers for Disease Control and Prevention (CDC): epidemiologic risk factors to consider when evaluating a person for exposure to Ebola virus]

• Body fluids remain infectious even after death. As a consequence, many infections have occurred at traditional funeral services in Africa where mourners touch the bodies of the deceased.[65] Super-spreading events in the community are also increasingly recognised as a contributing factor: a funeral of a traditional healer in Sierra Leone in 2015 was linked to 300 cases.[37] In one study, it was found that super-spreaders were responsible for approximately 61% of infections in the 2014 outbreak.[38]

• Sexual transmission has been documented during active infection. The virus can still be detected in semen more than 9 months after recovery from infection, possibly due to testicular tissue being an immunologically-protected site.[42] This means that sexual transmission may be possible long after the infection has resolved.[39] [40] [41] [43] [44] and such cases were confirmed during the 2014 outbreak.[45] [46] [47]

occupational exposure

• Healthcare workers in contact with infected patients are at high risk, and most epidemics have resulted in numerous infections in healthcare professionals.

• Needlestick injuries from an infected donor are a very high-risk exposure depending on the inoculum and nature of the injury. Use of non-sterile needles was responsible for the nosocomial spread of the first epidemic in 1976.[24] Accidental needle exposure has occurred in research laboratories in the UK, Russia, and Germany. The incubation periods in such cases may be considerably shorter compared with human-to-human transmission.[11] [18] [40]

• Other high-risk occupations include those where people work with primates or bats from endemic areas, or high-risk clinical samples.

butchering or consumption of meat from infected (or potentially infected) animals

• This route of transmission is likely to be a cause of animal-to-human transmission in sporadic epidemics.[66]

Weak

bioterrorism

• Ebola virus has long been considered a potential bioterrorism weapon due to its high case fatality rate and the ease of human-to-human transmission. However, despite its potential, there is no evidence that the Ebola virus has been used as a weapon.[67]

History & examination factors

Key diagnostic factors

presence of risk factors (common)

• Key risk factors include: living or working in, or arrival from, an endemic area in previous 21 days; contact with infected body fluids; occupational exposure; or butchering/consumption of meat from infected (or potentially infected) animals.

exposure to Ebola virus in previous 21 days (common)
Diagnosis

• Human-to-human transmission occurs via contact with body fluids (e.g., sweat, blood, faeces, vomit, saliva, genital secretions [including semen], and breast milk) from infected patients.[34] [39] Virus levels in these fluids are particularly high in more severe or advanced infection. The incubation period after infection is 1 to 21 days (typically 5-12 days) in 95% of patients,[2] [3] with a mean of 11.4 days in the 2014 outbreak.[3] Incubation periods may be shorter in children.[4]

• Contacts of infected patients (including healthcare workers and household contacts) are at risk of infection if the person was exposed to body fluids of the infected patient without appropriate protective equipment. Household contacts of infected patients are at a higher risk of infection if there is active diarrhoea, vomiting, or bleeding.[34]

• Epidemiological risk factors are divided into the following categories: high risk, some risk, low (but not zero) risk, and no identifiable risk. [Centers for Disease Control and Prevention (CDC): epidemiologic risk factors to consider when evaluating a person for exposure to Ebola virus]

• Body fluids remain infectious even after death. As a consequence, many infections have occurred at traditional funeral services in Africa where mourners touch the bodies of the deceased. Super-spreading events in the community are also increasingly recognised as a contributing factor: a funeral of a traditional healer in Sierra Leone in 2015 was linked to 300 cases.[37] In one study, it was found that super-spreaders were responsible for approximately 61% of infections in the 2014 outbreak.[38]

• People who have travelled to endemic areas are considered to be at high risk of infection. Up-to-date knowledge of the geographical locations of active epidemics helps to clarify the patient’s epidemiological risk.

fever ≥37.5°C (common)

• Presenting symptom in approximately 90% of patients, and is often >39.0°C with a remitting pattern.[3] [90] Some patients may initially have a low-grade fever with no other symptoms, or alternatively the temperature may be near normal at first evaluation.[91] In a large cohort in Sierra Leone, <30% had a fever of ≥38°C at presentation, although a history of fever was reported by 89% of patients.[22]

• The temperature threshold for fever differs among countries and guidelines, and using a lower temperature threshold increases the sensitivity of finding cases.[90] [92]

• Reported in 87% to 89% of patients in the 2014 outbreak.[3] [22]

• Presence is enough to raise concern for infection in the appropriate epidemiological context.

• Patients are often normothermic or hypothermic in the later stages of fatal infection.[17] [18] [87]

myalgia (common)

• Common feature of infection, present in up to 80% of patients in previous outbreaks.[10] [18]

• Reported in 22% to 38% of patients in the 2014 outbreak. Raised creatine kinase was common (36% to 83%).[3] [19] [81] [84] [85]

• May be associated with arthralgia and persist through convalescence.

conjunctival injection (common)

• Early sign of infection in approximately 40% of laboratory-confirmed cases in some outbreaks.[18] [87] [108]

Other diagnostic factors

fatigue (common)
• Severe tiredness and lethargy is a common feature in up to 90% of cases in previous outbreaks.[18] [87]
• Reported in 76% of patients in the 2014 outbreak.[3]

diarrhoea (common)
• Common feature of infection, present in 88% of patients in a previous outbreak.[18]
• Reported in 65% of patients in the 2014 outbreak.[3]
• May be bloody.
• Cholera beds may be used for cases of profuse diarrhoea in undeveloped countries. [Fig-5]

nausea/vomiting (common)
• Common feature of infection, present in 65% to 70% of patients in previous outbreaks.[10] [18]
• Vomiting reported in 67% of patients in the 2014 outbreak.[3]
• Vomit may contain blood.

severe headache (common)
• Non-specific feature of early infection, present in 10% to 70% of patients in previous outbreaks.[18] [87]
• Reported in 53% of patients in the 2014 outbreak.[3]
• Meningism has been observed rarely.

abdominal pain or heartburn (common)
• Reported in 44% of patients in the 2014 outbreak.[3]
• It may be difficult to distinguish heartburn from lower anterior chest pain or dysphagia. Dysphagia and heartburn are likely due to oesophagitis.

cough, dyspnoea, chest pain (common)
• Chest pain and cough reported in 10% and 7% of patients respectively in the 2014 outbreak;[19] however, direct involvement of the lungs has only rarely been reported.[83]
• Difficulty breathing reported in 20% to 23% of patients in the 2014 outbreak.[3] [19]
• Respiratory symptoms tend to be more common in children compared with adults; however, data are limited.[87] [88]

sore throat (common)
• Pharyngitis is a non-specific feature, present in 10% to 58% of patients in previous outbreaks.[18] [87]
• Reported in 9% of patients in the 2014 outbreak.[19]
• May cause dysphagia, which was reported in 26% to 32% of patients in the 2014 outbreak.[3] [19]

prostration (common)
• Profound prostration is a typical finding reported in 73% of patients in the 2014 outbreak.[85]

tachypnoea (common)
• Present in 31% of fatal infections in a previous outbreak and not seen in any survivors.[17] [18]
• Reported in 5% of patients in the 2014 outbreak.[85]
• May reflect metabolic acidosis due to uraemia and hypoperfusion.

maculopapular rash (uncommon)
Ebola virus infection

Diagnosis

• Developed early in the course of illness in approximately 25% to 52% of patients in previous outbreaks.[17]
• Reported in 1% to 5% of patients in the 2014 outbreak.[3] [19] [85]
• Frequently described as non-pruritic, erythematous, and maculopapular. It may begin focally, then become diffuse, generalised, and confluent. Some have described it as morbilliform. May become purpuric or petechial later on in the infection in patients with coagulopathy.[23]
• May be difficult to discern in dark-skinned patients.

bleeding (uncommon)

• Presence suggests advanced infection and presence of disseminated intravascular coagulation.
• Bleeding manifestations (e.g., epistaxis, bleeding gums, haemoptysis, easy bruising, conjunctival bleeding, haematuria, oozing from injection or venipuncture sites) were present in 30% to 36% of infected patients in previous outbreaks;[12] [17] [18] however, they were reported in only 5% to 18% of patients in the 2014 outbreak.[3] [19] [20] [21] [22]
• Massive bleeding is usually only observed in fatal cases, and typically occurs in the gastrointestinal tract (e.g., melaena, bloody diarrhoea).[17] In a previous outbreak, melaena was present in 8% of fatal infections and 16% of survivors.[18]
• Internal bleeding may be missed if there are no external signs.
• Bleeding manifestations are less common in children.[89]

hepatomegaly (uncommon)

• In a previous outbreak, tender hepatomegaly with the edge of the liver palpable below the rib cage was present in 2% of fatal infections and 8% of survivors.[18]

lymphadenopathy (uncommon)

• Enlarged lymph nodes have been reported.[17]

hiccups (uncommon)

• Sign of advanced infection and poor prognosis, typically seen in the last 2 to 3 days of fatal infections.[17]
• May be due to uraemia, hypokalaemia, hyponatraemia, hypocalcaemia, or hypocarbia due to respiratory compensation of metabolic acidosis.
• In a previous outbreak, hiccups were present in 17% of fatal infections and 5% of survivors.[18]
• Reported in 11% of patients in the 2014 outbreak.[3] [85]
• Less common in children.[89]

tachycardia (uncommon)

• May be seen in the later stages of fatal infections.[17]

hypotension (uncommon)

• Feature of pre-terminal disease and shock. It is under-documented in field studies owing to a lack of measuring equipment in endemic areas.[17]
• However, septic shock with vascular leakage and microcirculatory failure does not appear to be a dominant feature.

neurological signs (uncommon)

• Confusion was reported in 19% of patients in the 2014 outbreak. It appeared to be more common compared with previous outbreaks, and is a predictor of death.[85] [89]
Ebola virus infection

Diagnosis

• Often co-exist with bleeding and hypotension making fluid resuscitation hazardous.
• Encephalopathy is possibly related to electrolyte disturbances, uraemia, and cerebral hypoperfusion in terminal infection.
• Seizures occurred in 2% of fatal infections in a previous outbreak.[18]

Diagnostic tests

1st test to order

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>reverse transcriptase-polymerase chain reaction (RT-PCR)</td>
<td>positive for Ebola virus RNA</td>
</tr>
<tr>
<td>• Should be ordered in all patients with suspected Ebola infection while the patient is in isolation.[93]</td>
<td></td>
</tr>
<tr>
<td>• Returns result 24 to 48 hours before ELISA testing.</td>
<td></td>
</tr>
<tr>
<td>• Several different commercial PCR kits are available with varying sensitivity, specificity, and limits of detection.[94]</td>
<td></td>
</tr>
<tr>
<td>• In Western settings, the test may only be available in regional or national laboratories that have category 4 facilities.[11] In epidemic settings and some countries, category 4 laboratories are set up locally and results are available 4 hours after the sample has arrived.</td>
<td></td>
</tr>
<tr>
<td>• Viral RNA can be detected in the patient’s blood by RT-PCR from day 3 up to days 6 to 17 of symptom onset. A positive PCR result implies that the patient is potentially infective, particularly if he or she has active diarrhoea, vomiting, or bleeding.</td>
<td></td>
</tr>
<tr>
<td>• If negative, the test should be repeated within 48 hours since viral load is low and can be undetectable early in the course of the illness. Negative tests should be repeated to rule out a diagnosis if it is strongly suspected (or confirm resolution of infection).[93]</td>
<td></td>
</tr>
<tr>
<td>• Higher viral load correlates with adverse outcome and increased mortality.[20] [21] [60] [81] [93] [95]</td>
<td></td>
</tr>
<tr>
<td>malaria investigations</td>
<td>negative (may be positive if dual infection)</td>
</tr>
<tr>
<td>• Giemsa-stained thick and thin blood smears and rapid diagnostic tests are the tests of choice for malaria screening.</td>
<td></td>
</tr>
<tr>
<td>• A negative result makes Ebola virus infection more likely in the appropriate epidemiological context; however, co-infection with malaria was seen in up to 5% of patients in West Africa during the 2014 outbreak, so the possibility of dual infection should be considered in all patients.[81]</td>
<td></td>
</tr>
</tbody>
</table>
**Other tests to consider**

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>serum electrolyte levels</strong></td>
<td>may be abnormal</td>
</tr>
<tr>
<td>• Important test to order (if available) in areas where other investigations are limited.</td>
<td></td>
</tr>
<tr>
<td>• May indicate acute kidney injury.</td>
<td>[97]</td>
</tr>
<tr>
<td>• Especially useful in patients with diarrhoea and vomiting.</td>
<td></td>
</tr>
<tr>
<td>• Hypokalaemia or hyperkalaemia, due to vomiting and diarrhoea or acute kidney injury, was seen in approximately 33% of cases in the 2014 outbreak.</td>
<td>[81]</td>
</tr>
<tr>
<td>• Hypocalcaemia has been associated with fatal infection.</td>
<td>[17]</td>
</tr>
<tr>
<td>• Useful to guide correction of electrolytes and fluid replacement.</td>
<td></td>
</tr>
<tr>
<td><strong>serum creatinine and urea</strong></td>
<td>may be elevated</td>
</tr>
<tr>
<td>• Important test to order (if available) in areas where other investigations are limited.</td>
<td></td>
</tr>
<tr>
<td>• May indicate acute kidney injury, which was common in the 2014 outbreak,</td>
<td>[22] [97] and was associated with death.</td>
</tr>
<tr>
<td>• Especially useful in patients with diarrhoea and vomiting.</td>
<td></td>
</tr>
<tr>
<td><strong>blood lactate</strong></td>
<td>variable</td>
</tr>
<tr>
<td>• Important test to order (if available) in areas where other investigations are limited.</td>
<td></td>
</tr>
<tr>
<td>• Elevated lactate is a marker of tissue hypoperfusion and is an indicator of shock. It is useful in acutely ill patients with signs of sepsis to identify the degree of systemic hypoperfusion and to guide fluid resuscitation.</td>
<td>[98]</td>
</tr>
<tr>
<td>• Elevated lactate was one indicator of gram-negative sepsis at day 15 in a patient treated in Germany.</td>
<td>[36]</td>
</tr>
<tr>
<td><strong>ABG</strong></td>
<td>variable</td>
</tr>
<tr>
<td>• Arterial or venous blood pH and bicarbonate are useful in acutely ill patients with signs of sepsis to identify the degree of systemic hypoperfusion and guide fluid resuscitation.</td>
<td>[98]</td>
</tr>
<tr>
<td><strong>FBC</strong></td>
<td>thrombocytopenia, marked lymphopenia; decreased haemoglobin (if bleeding manifestations)</td>
</tr>
<tr>
<td>• Decrease in platelet count and marked lymphopenia can be seen in the initial stages of infection; however, this is not diagnostic. Often followed by neutrophil leukocytosis in the later stages of patients who eventually recover, along with normalisation of thrombocytopenia. Leukocytosis may persist and show immature forms.</td>
<td>[17]</td>
</tr>
<tr>
<td>• Patients with severe disease may show a progressive decline in platelet count as a manifestation of disseminated intravascular coagulation (DIC).</td>
<td></td>
</tr>
<tr>
<td>• Decreased haemoglobin levels were reported in 24% of patients in the 2014 outbreak, and have been associated with bleeding in previous outbreaks.</td>
<td>[17]</td>
</tr>
<tr>
<td><strong>coagulation studies</strong></td>
<td>prolonged PT or aPTT, elevated D-dimer level (if bleeding manifestations)</td>
</tr>
<tr>
<td>• Prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT) is associated with more severe infection and bleeding manifestations such as DIC.</td>
<td></td>
</tr>
<tr>
<td>• Patients with fatal infection have been found to have D-dimer levels four-fold higher on days 6 to 8 of infection compared with patients who survive.</td>
<td>[99]</td>
</tr>
</tbody>
</table>
## Diagnosis

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>urinalysis</strong></td>
<td>may show haematuria or proteinuria</td>
</tr>
<tr>
<td>• Haematuria or proteinuria may be seen in severe disease.[17]</td>
<td></td>
</tr>
<tr>
<td>• Oliguria that does not respond to fluid resuscitation is a poor</td>
<td></td>
</tr>
<tr>
<td>prognostic sign.</td>
<td></td>
</tr>
<tr>
<td><strong>LFTs</strong></td>
<td>high AST:ALT ratio; bilirubin, GGT, and ALP may be slightly elevated</td>
</tr>
<tr>
<td>• Both ALT and AST are usually elevated; however, most studies show</td>
<td></td>
</tr>
<tr>
<td>that AST rises out of proportion to ALT, and this is more suggestive</td>
<td></td>
</tr>
<tr>
<td>of systemic tissue damage rather than hepatocellular injury.[81]</td>
<td></td>
</tr>
<tr>
<td>• AST:ALT ratio peaked at 15:1 on days 6 to 8 of infection in fatal</td>
<td></td>
</tr>
<tr>
<td>cases when compared with non-fatal cases, which had a peak of 5:1.[9]</td>
<td></td>
</tr>
<tr>
<td>[17]</td>
<td></td>
</tr>
<tr>
<td>[99]</td>
<td></td>
</tr>
<tr>
<td>• Bilirubin, GGT, and ALP are often slightly elevated. Highly elevated</td>
<td></td>
</tr>
<tr>
<td>ALT and severe jaundice suggests an alternative diagnosis (e.g., viral</td>
<td></td>
</tr>
<tr>
<td>hepatitis).</td>
<td></td>
</tr>
<tr>
<td><strong>serum amylase level</strong></td>
<td>may be elevated</td>
</tr>
<tr>
<td>• Elevated levels have been reported in several studies and indicates</td>
<td></td>
</tr>
<tr>
<td>the presence of pancreatitis, an indicator of severe infection.[17]</td>
<td></td>
</tr>
<tr>
<td><strong>blood cultures</strong></td>
<td>negative</td>
</tr>
<tr>
<td>• Negative blood cultures are helpful as they rule out other non-viral</td>
<td></td>
</tr>
<tr>
<td>infectious causes (e.g., sepsis, enteric fever).</td>
<td></td>
</tr>
<tr>
<td>• Gram-negative bacteraemia, presumably from gut translocation, was</td>
<td></td>
</tr>
<tr>
<td>identified as a complication of the disease course in one patient who</td>
<td></td>
</tr>
<tr>
<td>was repatriated to Germany.[36] However, a study in Sierra Leone</td>
<td></td>
</tr>
<tr>
<td>where blood cultures were taken from patients on admission to an</td>
<td></td>
</tr>
<tr>
<td>Ebola treatment centre found that only one of the 22 cultures was</td>
<td></td>
</tr>
<tr>
<td>positive with a presumed contaminant.[100]</td>
<td></td>
</tr>
<tr>
<td>• Therefore, blood should be collected for culture at baseline and/or</td>
<td></td>
</tr>
<tr>
<td>at the time of the onset of gastrointestinal symptoms or other clinical</td>
<td></td>
</tr>
<tr>
<td>deterioration.</td>
<td></td>
</tr>
<tr>
<td><strong>antigen-capture enzyme-linked immunosorbent assay (ELISA)</strong></td>
<td>positive for Ebola virus antibodies</td>
</tr>
<tr>
<td>• Useful diagnostic test with high specificity; however, it is not</td>
<td></td>
</tr>
<tr>
<td>universally available. Can be used to confirm the diagnosis along with</td>
<td></td>
</tr>
<tr>
<td>a positive RT-PCR result.</td>
<td></td>
</tr>
<tr>
<td>• Most likely to give a positive result from day 3 until day 6 of</td>
<td></td>
</tr>
<tr>
<td>infection, and can give widely variable results from days 7 to 16.[41]</td>
<td></td>
</tr>
<tr>
<td><strong>IgM and IgG antibodies</strong></td>
<td>positive</td>
</tr>
<tr>
<td>• Useful in later stages of the infection.</td>
<td></td>
</tr>
<tr>
<td>• IgM antibodies can appear in serum as early as day 2 post infection</td>
<td></td>
</tr>
<tr>
<td>but can give variable results up to day 9. They become negative</td>
<td></td>
</tr>
<tr>
<td>between 30 and 168 days after symptom onset. IgG response develops</td>
<td></td>
</tr>
<tr>
<td>between day 6 and 18 and can persist for several years.[41]</td>
<td></td>
</tr>
<tr>
<td>• A positive IgM or a rising IgG titre is strong evidence for recent</td>
<td></td>
</tr>
<tr>
<td>Ebola virus infection.</td>
<td></td>
</tr>
<tr>
<td><strong>chest x-ray</strong></td>
<td>negative</td>
</tr>
<tr>
<td>• Useful in patients with respiratory symptoms.</td>
<td></td>
</tr>
<tr>
<td>• Pulmonary infiltrates are not typical of infection and suggest an</td>
<td></td>
</tr>
<tr>
<td>alternative (or comorbid) diagnosis.</td>
<td></td>
</tr>
<tr>
<td>• May be difficult to arrange in an isolation unit and should only be</td>
<td></td>
</tr>
<tr>
<td>ordered judiciously to avoid contamination.[101]</td>
<td></td>
</tr>
</tbody>
</table>
## Emerging tests

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>rapid bedside tests</td>
<td>positive for Ebola virus</td>
</tr>
</tbody>
</table>

- Rapid PCR testing for Ebola virus infection remains a major hurdle for effective, targeted isolation of affected patients. Current tests take an average of 4 hours to perform with a fully equipped laboratory close at hand, but results may take several days to arrive in remote areas. This means that, until they are confirmed negative, patients with febrile illnesses other than Ebola virus infection are confined to isolation and often unwittingly exposed to the virus.
- Rapid bedside tests can therefore make a very significant contribution to infection control in treatment centres.
- Several different technologies are being evaluated by WHO for use in field conditions. These include numerous RT-PCR-based assays that have been made simpler to use with a shorter turnaround time of <1 hour. The WHO has listed ReEBOV™ Antigen Rapid Test Kit for potential use; however, it currently only recommends its use in special situations. [World Health Organization (WHO): interim guidance on the use of rapid Ebola antigen detection tests]
- The alternatives are ELISA-based antigen-detection assays that could be quicker and simpler with the possible advantage of only needing a drop of blood. Their major disadvantage is a reduced sensitivity, particularly in the initial stages of illness. [102]
- Nanopore technology may allow rapid detection and sequencing in the presence of very low levels of virus, and can potentially be deployed using a pocket-sized detection kit. [104] [105] [106]
- A GeneXpert® diagnostic tool (Xpert® Ebola) has been trialled in the field, and is an automated cartridge-based system that requires minimal laboratory skill. An inactivated sample is placed into a single-use cartridge, which is then entered into the enclosed machine. Sample preparation, nucleic acid amplification and detection, and production of a result are automated processes minimising staff training requirements, risk of infection, and cross contamination. [107]
- This is a rapidly evolving field and different kits are approved according to the country and settings in which they are to be deployed. WHO and Food and Drug Administration (FDA) recommendations are available: [World Health Organization (WHO): Ebola vaccines, therapies, and diagnostics] [Food and Drug Administration (FDA): 2014 Ebola virus emergency use authorizations]
## Differential diagnosis

<table>
<thead>
<tr>
<th>Condition</th>
<th>Differentiating signs / symptoms</th>
<th>Differentiating tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malaria infection</td>
<td>• Most common cause of non-specific febrile illness in returning travellers.[96]</td>
<td>• Giemsa-stained thick and thin blood smears: positive for <em>Plasmodium</em> species.</td>
</tr>
<tr>
<td></td>
<td>• Inadequate or no malaria chemoprophylaxis.</td>
<td>• Rapid diagnostic tests: positive for <em>Plasmodium</em> species (note: <em>P ovale</em> is not always detected by some rapid diagnostic tests).</td>
</tr>
<tr>
<td></td>
<td>• There are no differentiating signs and symptoms.</td>
<td>• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
<tr>
<td></td>
<td>• Co-infection with malaria was seen in up to 5% of patients in West Africa during the 2014 outbreak, so the possibility of dual infection should be considered in all patients.[81]</td>
<td></td>
</tr>
<tr>
<td>Marburg virus infection</td>
<td>• There are no differentiating signs and symptoms.</td>
<td>• Reverse transcriptase-polymerase chain reaction (RT-PCR): positive for Marburg virus RNA.</td>
</tr>
<tr>
<td></td>
<td>• Epidemiological features can help differentiate between the viral haemorrhagic fevers (i.e., exposure to bats, caves, or mining).[109]</td>
<td>• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
<tr>
<td>Crimean-Congo haemorrhagic fever (CCHF)</td>
<td>• There are no differentiating signs and symptoms.</td>
<td>• RT-PCR: positive for CCHF virus RNA.</td>
</tr>
<tr>
<td></td>
<td>• Epidemiological features can help differentiate between the viral haemorrhagic fevers (i.e., animal butchering, tick bite, or exposure to animals).[110]</td>
<td>• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
<tr>
<td>Lassa fever</td>
<td>• There are no differentiating signs and symptoms.</td>
<td>• RT-PCR: positive for Lassa virus RNA.</td>
</tr>
<tr>
<td></td>
<td>• Epidemiological features can help differentiate between the viral haemorrhagic fevers (i.e., exposure to rats in endemic areas).[111]</td>
<td>• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
<tr>
<td>Condition</td>
<td>Differentiating signs / symptoms</td>
<td>Differentiating tests</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Rift Valley fever       | • There are no differentiating signs and symptoms.  
• Epidemiological features can help differentiate between the viral haemorrhagic fevers (i.e., mosquito exposure, livestock handling, consuming raw animal fluids/tissues).                                                                                      | • RT-PCR: positive for Rift Valley fever virus RNA.  
• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.                                                                |
| Yellow fever            | • There are no differentiating signs and symptoms.  
• Epidemiological features can help differentiate between the viral haemorrhagic fevers (i.e., mosquito exposure, lack of immunisation).                                                                                           | • RT-PCR: positive for yellow fever virus RNA.  
• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.                                                                |
| Typhoid infection       | • There are no differentiating signs and symptoms.                                                                                                                                                                                                                                                                                                               | • Blood or stool culture: positive for *Salmonella enterica*.  
• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.                                                                |
| Rickettsial infections  | • Includes murine typhus, African tick-bite fever, and epidemic typhus.[112]  
• Eschar is typical.  
• Lymphadenopathy may be present.  
• Discrete rash.                                                                                                                                                                                                                                                                                       | • Serology: positive for *Rickettsia* species.  
• Eschar PCR: positive for *Rickettsia* species.  
• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.                                                                |

[112] This PDF of the BMJ Best Practice topic is based on the web version that was last updated: Jul 31, 2017. BMJ Best Practice topics are regularly updated and the most recent version of the topics can be found on bestpractice.bmj.com. Use of this content is subject to our disclaimer. © BMJ Publishing Group Ltd 2018. All rights reserved.
<table>
<thead>
<tr>
<th>Condition</th>
<th>Differentiating signs / symptoms</th>
<th>Differentiating tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue fever</td>
<td>• There are no differentiating signs and symptoms.</td>
<td>• Serology: positive IgM or IgG.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Non-structural protein (NS1) detection: positive.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Reverse transcriptase-polymerase chain reaction (RT-PCR): positive.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
<tr>
<td>Measles infection</td>
<td>• Unvaccinated.</td>
<td>• Serology: positive for measles virus.</td>
</tr>
<tr>
<td></td>
<td>• There are no differentiating signs and symptoms in prodromal phase.</td>
<td>• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
<tr>
<td></td>
<td>• Koplik's spots (red spots with bluish-white central dot) on buccal mucosa.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Rash typically starts on face and spreads craniocaudally.</td>
<td></td>
</tr>
<tr>
<td>Leptospirosis</td>
<td>• There are no differentiating signs and symptoms; however, a history of exposure may be helpful.</td>
<td>• PCR: positive.</td>
</tr>
<tr>
<td></td>
<td>• Exposure to contaminated water or soil contaminated by infected rodents.[113]</td>
<td>• Serology: positive.</td>
</tr>
<tr>
<td></td>
<td>• More common in tropical climates.</td>
<td>• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
<tr>
<td>Seasonal influenza infection</td>
<td>• Respiratory signs and symptoms (e.g., cough, nasal congestion) are more common.</td>
<td>• Viral culture or PCR: detection of seasonal influenza virus or viral RNA.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• FBC: normal.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
<tr>
<td>Condition</td>
<td>Differentiating signs / symptoms</td>
<td>Differentiating tests</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>• In the correct epidemiological context, this can present in a similar way to Ebola virus infection. However, features such as rash, conjunctival injection, and prostration are very rare in gastroenteritis.</td>
<td>• Stool culture, PCR, or rapid antigen testing: positive. • It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
<tr>
<td>Sepsis</td>
<td>• Bacterial sepsis with an unclear origin is a common presentation in developing countries. Often turns out to be deep abdominal infection, upper urinary tract infection, endocarditis, or discitis. • Diarrhoea is often absent.</td>
<td>• Blood cultures: positive. • It is recommended that appropriate confirmatory tests for Ebola virus infection are performed before, or in tandem with, differentiating tests if Ebola virus infection is suspected.</td>
</tr>
</tbody>
</table>

### Diagnostic criteria

#### Case definitions

**World Health Organization case definition for Ebola or Marburg virus disease:**[82]

- [World Health Organization (WHO): case definition recommendations for Ebola or Marburg virus diseases]

**Centers for Disease Control and Prevention (CDC) case definition for Ebola virus disease (EVD):**[79]

- [Centers for Disease Control and Prevention (CDC): case definition for Ebola virus disease (EVD)]
Step-by-step treatment approach

The mainstay of treatment is early recognition of infection coupled with effective isolation and best available supportive care in a hospital setting.

High case fatality rates may be related to the supportive care available in resource-poor, rural settings where outbreaks have occurred, and reflect the difficulties patients in these settings have in accessing basic medical care in a healthcare structure that is overwhelmed.[3] [20]

Cases imported to developed countries such as Spain, Germany, France, Norway, Italy, Switzerland, the UK, and the US present a different scenario with comprehensive supportive care available in these settings, including organ support in intensive care units.[36] [114] Despite this, the lack of specific, proven therapies means that fatalities occur even in developed countries where best supportive care is available.[92] [115] [116]

There was previously an active debate about the suitability of moving patients with advanced disease and a poor prognosis to intensive care where the risk for nosocomial infection may be high. It was thought that failure to provide full supportive care to those who are suspected (but not confirmed) of being infected may result in substandard care for these patients, who may subsequently be shown to have a treatable disease such as malaria. It is now clear that full supportive care can reduce mortality, with a reported survival rate of 81.5% in patients managed outside the West African setting, and that it should be provided whenever possible.[117] [118] [119] Local hospital protocols should consider how this situation would be handled for patients with suspected infection before possible transfer to the intensive care unit, and for those who have already been transferred there.[98] [116] [118] [120] [121]

Children should be managed by teams of health care workers with paediatric expertise. Planning for the care of children in non-endemic settings is complex and early involvement of intensivists has been advocated whenever feasible.[122] [123] [124]

Ebola virus infection is a notifiable disease.

Isolation and infection control

Patients who are identified as being at risk of infection as per the World Health Organization (WHO) or Centers for Disease Control and Prevention (CDC) case definitions should immediately be isolated in a room with private bathroom facilities:

- [World Health Organization (WHO): case definition recommendations for Ebola or Marburg virus diseases]
- [Centers for Disease Control and Prevention (CDC): case definition for Ebola virus disease (EVD)]

All healthcare personnel attending to the patient must wear appropriate personal protective equipment (PPE) that conforms to published protocols. All contaminated materials (e.g., clothes, bed linens) should be treated as potentially infectious. The WHO and CDC produce detailed guidance on PPE:
Ebola virus infection

Treatment

- [World Health Organization (WHO): personal protective equipment in the context of Filovirus disease outbreak response - rapid advice guideline]
- [World Health Organization (WHO): steps to put on personal protective equipment (PPE)]
- [World Health Organization (WHO): steps to remove personal protective equipment (PPE)]
- [Centers for Disease Control and Prevention (CDC): guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation (PUIs) for Ebola]

The WHO and CDC produce detailed guidance on infection control for healthcare workers in West Africa:

- [World Health Organization (WHO): infection prevention and control (IPC) guidance summary]
- [Centers for Disease Control and Prevention (CDC): international infection control for healthcare workers (non-US healthcare settings)]

Specimens for laboratory investigations (e.g., Ebola RT-PCR, FBC, serum creatinine and urea, LFTs, ABG, coagulation studies, blood cultures, and investigations for other conditions such as malaria) should be collected and sent off according to local and national protocols. Judicious selection of investigations is important in order to reduce risk of transmission to laboratory workers and other healthcare personnel. Placement of a central line early in the patient stay (if possible) allows bloods to be taken and fluids to be given while minimising the risk of needlestick injuries. The WHO and CDC produce detailed guidance on specimen collection:

- [World Health Organization (WHO): how to safely collect blood samples from persons suspected to be infected with highly infectious blood-borne pathogens]
- [Centers for Disease Control and Prevention (CDC): guidance for collection, transport and submission of specimens for Ebola virus testing]

[Fig-3]

**Fluid and electrolyte replacement**

The high frequency of vomiting and diarrhoea means that patients are often dehydrated and hypovolaemic, particularly if they present late. This is probably responsible for the high case fatality rates in outbreaks as basic clinical monitoring (i.e., temperature, respiratory rate, pulse rate, blood pressure, and fluid input/output) is essential, but often difficult in resource-poor settings.

Oral rehydration solutions can be used for patients who can tolerate oral administration and who are not severely dehydrated, but the majority of patients require intravenous fluid replacement. Oral rehydration solutions can be used for patients who can tolerate oral administration and who are not severely dehydrated, but the majority of patients require intravenous fluid replacement.[20] [81] [Fig-9]

[Fig-10]

The volume of intravenous fluids required should be assessed based on clinical examination (i.e., level of dehydration, signs of shock) and fluid losses (i.e., volume of diarrhoea and/or vomitus). Large volumes of fluid replacement (up to 10 L/day) may be required in febrile patients with diarrhoea.[36] [126] [127] Large amounts of potassium replacement (e.g., 5-10 mmol [5-10 mEq/L] potassium chloride per hour) may also be required. [22] [114] [128]
Oral loperamide may help reduce profuse diarrhoea, but further evidence is required to determine its role and it is not currently recommended by the WHO.\[129\] \[130\] \[131\] \[132\]

The availability of point-of-care tests within the isolation facility makes monitoring the patient's biochemical status more efficient and reduces the risks associated with specimen transport.\[98\] Electrolyte monitoring should be performed daily.\[20\] More frequent monitoring can be considered if large volumes of intravenous fluids are being administered or if there are severe biochemical abnormalities present. High blood lactate levels can be a reliable measure of hypoperfusion and can help guide fluid resuscitation.\[98\]

WHO guidelines should be consulted for specific recommendations on fluid and electrolyte management as well as on maintaining adequate nutrition during acute illness and the convalescent phase.

[World Health Organization (WHO): manual for the care and management of patients in Ebola care units/ community care centres - interim emergency guidance]

[World Health Organization (WHO): clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker]

Symptomatic management

Fever and pain:

- Should be treated with paracetamol first line. Opioid analgesics (e.g., morphine) are preferable for more severe pain. Non-steroidal anti-inflammatory drugs (including aspirin) should be avoided due to their associated increased risk of bleeding and potential for nephrotoxicity.\[132\]

Nausea and vomiting:

- Oral or intravenous anti-emetics (e.g., ondansetron, metoclopramide) are recommended.\[132\]

Heartburn/dysphagia/abdominal pain:

- Patients may benefit from administration of a suitable antacid or a proton-pump inhibitor (e.g., omeprazole).\[132\]

Seizures:

- Although uncommon, seizures are a feature of advanced disease and pose a risk to healthcare workers because they increase the risk of contact with the patient's body fluids. Recognition and correction of contributing factors (e.g., high temperature, hypoperfusion, electrolyte disturbances) is essential. A benzodiazepine can be used to abort the seizure while an anticonvulsant (e.g., phenobarbital) can be given for repeated seizures.\[132\] If there is no intravenous access, it can be given intramuscularly or rectally.

Agitation:

- Although uncommon, agitation may be associated with encephalopathy, or possibly a direct effect of the virus on the brain, and can occur in advanced disease. Judicious use of a sedative (e.g., haloperidol or a benzodiazepine) is imperative for keeping the patient calm and preventing needlestick injuries in healthcare workers.\[132\]

Intraosseous access may be required in some patients.

[Fig-11]
**Sepsis/septic shock**

Identification of sepsis or septic shock should be done rapidly using established criteria.

Management follows the same principles as for bacterial sepsis. Local guidance should be followed, but should include:[133]

- Broad-spectrum antibiotics in the first hour after sending blood cultures
- Rapid intravenous fluid resuscitation with assessment of response
- Appropriate airway management and oxygen administration
- Monitoring of urine output preferably by urethral catheterisation.

Broad-spectrum antibiotics are used in patients with infection to target the presumed translocation of gut organisms. This is not backed by any evidence, and blood cultures are difficult to do safely in infected patients. In some settings, especially in endemic areas where there is poor access to diagnostic tests, patients are routinely given broad-spectrum antibiotics as part of the management protocol.

Blood lactate levels are a useful tool to help assess perfusion and response to resuscitation.

In the absence of a response to initial management, inotropic support should be considered, preferably via a central venous catheter in an intensive care unit where invasive monitoring enables more aggressive fluid, electrolyte, and acid-base balance correction.[98] [121]

The possibility of haemorrhage should be considered, particularly in patients with skin or mucosal bleeding.

WHO guidelines should be consulted for specific recommendations on the management of sepsis/septic shock.

[World Health Organization (WHO): manual for the care and management of patients in Ebola care units/ community care centres - interim emergency guidance]

[World Health Organization (WHO): clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker]

**Disseminated intravascular coagulation (DIC) and haemorrhage**

Major bleeding occurs infrequently, but is a manifestation of advanced infection that is usually fatal. When available, platelet and plasma transfusions should be given according to local protocols.[134]

**Organ dysfunction**

Multi-organ dysfunction is a common feature of advanced infection and includes acute kidney injury, pancreatitis, adrenal failure, and liver damage. Liver damage (e.g., hepatitis) is common; however, jaundice is not a common feature.[59] Renal dysfunction is common, but can be reversed with adequate fluid resuscitation in the initial stages.[59] In patients with anuria who do not respond to fluid resuscitation, renal replacement therapy has been used, although there are no trial data to support the efficacy of this intervention. Of the 5 critically ill patients in Europe and North America with multi-organ failure who were managed with both invasive mechanical ventilation and renal replacement therapy, 3 died.[36] [92] [114] [116] [135]
**Convalescent whole blood or plasma**

There is limited evidence from past outbreaks that transfusion of blood from convalescent patients could be beneficial in the acute phase of infection, and may reduce mortality.[10] [136] Use of convalescent plasma is likely to be more achievable and effective than use of whole blood.[137] [138] The WHO has issued interim guidelines on the use of convalescent blood/plasma. Trials carried out in Guinea have so far failed to show a survival benefit in patients treated with convalescent plasma, although the treatment appears to be safe with no severe complications documented.[139] [140]

[World Health Organization (WHO): use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks]

[World Health Organization (WHO): ethics of using convalescent whole blood and convalescent plasma during the Ebola epidemic]

**Malaria co-infection**

Malaria should be tested for and treated with appropriate antimalarial therapy if present while keeping in mind the patient's risk for Ebola virus infection and the possibility of a dual infection. In endemic settings, malaria treatment is usually given as part of the routine management protocol, with or without confirmation of the infection.

[Centers for Disease Control and Prevention (CDC): recommendations for managing and preventing cases of malaria in areas with Ebola]

**Pregnant women**

The reported case fatality rate has been higher (up to 96%) in pregnant women compared with non-pregnant women in previous outbreaks.[141]

The general medical management of pregnant women is the same as for any other person who is infected. Intrapartum haemorrhage and spontaneous abortion appear to be common in infected women; therefore, obstetric management should focus on monitoring for, and early treatment of, haemorrhagic complications.[21] [141] [142] [143] [144] Experience during the 2014 outbreak suggests that good outcomes can occasionally be achieved.[145]

Amniotic fluid has been shown to contain the virus, including when the level was found to be undetectable in blood. Therefore recommendations for delivery include avoiding the induction of labour, particularly rupturing of membranes.[145]

Recommendations for PPE use by healthcare workers caring for pregnant women are the same as for healthcare workers caring for non-pregnant adults. There are no data available to recommend one delivery method over another. Infected women or women with suspected infection are advised not to breastfeed unless breast milk has been shown to be PCR negative for Ebola virus. The WHO, CDC, and Public Health England have produced specific guidance for caring for pregnant women and neonates.

[World Health Organization (WHO): Ebola virus disease in pregnancy: screening and management of Ebola cases, contacts and survivors]

[Centers for Disease Control and Prevention (CDC): guidance for screening and caring for pregnant women with Ebola virus disease for healthcare providers in US hospitals]
**Experimental therapies**

As this is a rapidly developing area, the latest WHO guidance should be consulted. [World Health Organization (WHO): Ebola R&D landscape of clinical candidates and trials] See Emerging Therapies section.

[Centers for Disease Control and Prevention (CDC): Ebola treatment]

[Public Health England: Ebola virus disease - clinical management and guidance]

## Treatment details overview

Consult your local pharmaceutical database for comprehensive drug information including contraindications, drug interactions, and alternative dosing. (see Disclaimer)

### Acute

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Tx line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>all patients</strong></td>
<td>1st</td>
<td>isolation and infection control</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>fluid and electrolyte management</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>analgesia/antipyretic</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>anti-emetic</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>consider administration of broad-spectrum antibiotics</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>consider administration of convalescent whole blood or plasma</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>antacid or proton-pump inhibitor</td>
</tr>
<tr>
<td>with heartburn/</td>
<td>plus</td>
<td>benzodiazepine or anticonvulsant</td>
</tr>
<tr>
<td>dysphagia/abdominal pain</td>
<td></td>
<td>sedative</td>
</tr>
<tr>
<td></td>
<td></td>
<td>empirical antibiotic therapy + fluid</td>
</tr>
<tr>
<td>with seizures</td>
<td>plus</td>
<td>resuscitation + inotropic support + airway management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>support care</td>
</tr>
<tr>
<td>with agitation</td>
<td>plus</td>
<td>platelet/plasma transfusion</td>
</tr>
<tr>
<td>with sepsis/septic shock</td>
<td>plus</td>
<td>antimalarial therapy</td>
</tr>
<tr>
<td>with organ dysfunction</td>
<td>plus</td>
<td></td>
</tr>
<tr>
<td>with haemorrhage or disseminated</td>
<td>plus</td>
<td></td>
</tr>
<tr>
<td>intravascular coagulation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>with malaria</td>
<td>plus</td>
<td></td>
</tr>
<tr>
<td>Acute</td>
<td>( summary )</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>pregnant</td>
<td>plus monitoring and early treatment of complications</td>
<td></td>
</tr>
</tbody>
</table>
### Treatment options

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Tx line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>all patients</td>
<td>1st</td>
<td>isolation and infection control</td>
</tr>
</tbody>
</table>

- Patients who are identified as being at risk of infection as per the World Health Organization (WHO) or Centers for Disease Control and Prevention (CDC) case definitions should immediately be isolated in a room with private bathroom facilities.\[79\] \[82\]

- Epidemiological risk factors are divided into the following categories: high risk, some risk, low (but not zero) risk, and no identifiable risk. [Centers for Disease Control and Prevention (CDC): epidemiologic risk factors to consider when evaluating a person for exposure to Ebola virus]

- All healthcare personnel attending to the patient must wear appropriate personal protective equipment (PPE) that conforms to published protocols. [Fig-3]

- All contaminated materials (e.g., clothes, bed linens) should be treated as potentially infectious.

- Specimens for laboratory investigations (e.g., Ebola RT-PCR, FBC, serum creatinine and urea, LFTs, ABG, coagulation studies, blood cultures, and investigations for other conditions such as malaria) should be collected and sent off according to local and national protocols. Judicious selection of investigations is important in order to reduce risk of transmission to laboratory workers and other healthcare personnel. [World Health Organization (WHO): personal protective equipment in the context of Filovirus disease outbreak response - rapid advice guideline]  [Centers for Disease Control and Prevention (CDC): guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation (PUIs) for Ebola]

- All healthcare personnel attending to the patient must wear appropriate personal protective equipment (PPE) that conforms to published protocols. [Fig-3]
<table>
<thead>
<tr>
<th>Acute</th>
<th>Tx line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient group</td>
<td></td>
<td>(CDC): guidance for collection, transport and submission of specimens for Ebola virus testing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Placement of a central line early in the patient stay (if possible) allows bloods to be taken and fluids to be given while minimising the risk of needlestick injuries.[125]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Ebola virus infection is a notifiable disease.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>plus fluid and electrolyte management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Oral rehydration solutions can be used for patients who can tolerate oral administration and who are not severely dehydrated, but the majority of patients require intravenous fluid replacement.[20] [81] [Fig-9]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[Fig-10]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» The volume of intravenous fluids required should be assessed based on clinical examination (i.e., level of dehydration, signs of shock) and fluid losses (i.e., volume of diarrhoea and/or vomitus). Large volumes of fluid replacement (up to 10 L/day) may be required in febrile patients with diarrhoea.[36]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» The availability of point-of-care tests within the isolation facility makes monitoring the patient’s biochemical status more efficient and reduces the risks associated with specimen transport.[98] Electrolyte monitoring should be performed daily.[20] More frequent monitoring can be considered if large volumes of intravenous fluids are being administered or if there are severe biochemical abnormalities present.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Large amounts of potassium replacement (e.g., 5-10 mmol [5-10 mEq/L] potassium chloride per hour) may be required.[22] [114] [128]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» High blood lactate levels can be a reliable measure of hypoperfusion and can help guide fluid resuscitation.[98]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» WHO guidelines should be consulted for specific recommendations on fluid and electrolyte management as well as on maintaining adequate nutrition during acute illness and the convalescent phase.</td>
</tr>
</tbody>
</table>
| | | » [World Health Organization (WHO): clinical management of patients with viral haemorrhagic
<table>
<thead>
<tr>
<th>Patient group</th>
<th>Tx line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute</td>
<td></td>
<td>fever: a pocket guide for the front-line health worker</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» [World Health Organization (WHO): manual for the care and management of patients in Ebola care units/community care centres - interim emergency guidance]</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>analgesia/antipyretic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Should be treated with paracetamol first line (for pain and fever).[132]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Opioid analgesics (e.g., morphine) are preferable for more severe pain.[132]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Non-steroidal anti-inflammatory drugs (including aspirin) should be avoided due to their associated increased risk of bleeding and potential for nephrotoxicity.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Analgesia may help dysphagia, if present.</td>
</tr>
</tbody>
</table>

**Primary options**

- **paracetamol**: children: 10-15 mg/kg orally/rectally every 4-6 hours when required, maximum 75 mg/kg/day; adults: 500-1000 mg orally/rectally every 4-6 hours when required, maximum 4000 mg/day

**OR**

**Secondary options**

- **morphine sulfate**: children: 0.2 to 0.4 mg/kg orally every 4-6 hours when required, or 0.05 to 0.1 mg/kg intravenously every 4-6 hours when required; adults: 2.5 to 10 mg orally/intravenously every 4 hours when required

**plus** anti-emetic

- Oral or intravenous anti-emetics (e.g., ondansetron, metoclopramide) are recommended.[132]

**Primary options**

- **metoclopramide**: children: consult specialist for guidance on dose; adults: 10 mg orally/intravenously every 8 hours, maximum 30 mg/day

**OR**

**Primary options**
## Acute

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Tx line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em>ondansetron</em>: children: consult specialist for guidance on dose; adults: 4-8 mg orally/intravenously every 8-12 hours when required, maximum 24 mg/day</td>
</tr>
<tr>
<td></td>
<td><strong>plus</strong></td>
<td>consider administration of broad-spectrum antibiotics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In some settings, especially in endemic areas where there is poor access to diagnostic tests, patients are routinely given broad-spectrum antibiotics as part of the management protocol.</td>
</tr>
<tr>
<td></td>
<td><strong>plus</strong></td>
<td>consider administration of convalescent whole blood or plasma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>There is limited evidence from past outbreaks that transfusion of blood from convalescent patients could be beneficial in the acute phase of infection, and may reduce mortality.[10] [136] Use of convalescent plasma is likely to be more achievable and effective than use of whole blood.[137] [138]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The WHO has issued interim guidelines on the use of convalescent blood/plasma.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trials carried out in Guinea have so far failed to show a survival benefit in patients treated with convalescent plasma, although the treatment appears to be safe with no severe complications documented.[139] [140]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[World Health Organization (WHO): use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[World Health Organization (WHO): ethics of using convalescent whole blood and convalescent plasma during the Ebola epidemic]</td>
</tr>
<tr>
<td></td>
<td><strong>plus</strong></td>
<td>antacid or proton-pump inhibitor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patients may benefit from administration of a suitable antacid or a proton-pump inhibitor (e.g., omeprazole).[132] Analgesia may help with dysphagia.</td>
</tr>
</tbody>
</table>

### Primary options

- **with heartburn/dysphagia/abdominal pain**
  - **plus** antacid or proton-pump inhibitor
  - Patients may benefit from administration of a suitable antacid or a proton-pump inhibitor (e.g., omeprazole).[132] Analgesia may help with dysphagia.

- **with seizures**
  - **plus** benzodiazepine or anticonvulsant
Although uncommon, seizures are a feature of advanced disease and pose a risk to healthcare workers because they increase the risk of contact with the patient's body fluids.

Recognition and correction of contributing factors (e.g., high temperature, hypoperfusion, electrolyte disturbances) is essential.

A benzodiazepine (e.g., intravenous/intramuscular or rectal diazepam) can be used to abort the seizure while an anticonvulsant (e.g., phenobarbital) can be given for repeated seizures.\[132\]

**Primary options**

- **Diazepam**
  - Children: consult specialist for guidance on dose; adults: 5-10 mg intravenously/intramuscularly initially, repeat every 10-15 minutes if required, maximum 30 mg/total dose
  - OR
    - **Diazepam rectal**: children: consult specialist for guidance on dose; adults: 0.2 mg/kg rectally as a single dose, a second dose can be given in 4-12 hours if necessary

--AND/OR--

- **Phenobarbital**
  - Children: consult specialist for guidance on dose; adults: 10 mg/kg intravenously initially, followed by 5 mg/kg every 30-60 minutes until seizures under control, maximum total loading dose 30 mg/kg

**with agitation** plus **sedative**

- Although uncommon, agitation may be associated with encephalopathy or possibly a direct effect of the virus on the brain, and can occur in advanced disease.

- Judicious use of a sedative (e.g., haloperidol or a benzodiazepine) is imperative for keeping the patient calm and preventing needlestick injuries in healthcare workers.\[132\]

- Repeat doses are based on clinical response.

**Primary options**

- **Diazepam**: children: consult specialist for guidance on dose; adults: 5 mg orally/intravenously as a single dose

OR
## Acute

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Tx line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>with sepsis/septic shock</td>
<td>plus</td>
<td>empirical antibiotic therapy + fluid resuscitation + inotropic support + airway management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identification of sepsis or septic shock should be done rapidly using established criteria. Management follows the same principles as for bacterial sepsis. Local guidance should be followed, but should include: broad-spectrum antibiotics in the first hour after sending blood cultures; rapid intravenous fluid resuscitation with assessment of response; appropriate airway management and oxygen administration; and monitoring of urine output preferably by urethral catheterisation.[133]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Blood lactate levels are a useful tool to help assess perfusion and response to resuscitation.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In the absence of a response to initial management, inotropic support should be considered, preferably via a central venous catheter in an intensive care unit where invasive monitoring enables more aggressive fluid, electrolyte, and acid-base balance correction.[98] [121]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Possibility of haemorrhage should be considered, particularly in patients with skin or mucosal bleeding.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WHO guidelines should be consulted for specific recommendations on the management of sepsis/septic shock.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[World Health Organization (WHO): clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[World Health Organization (WHO): manual for the care and management of patients in Ebola care units/community care centres - interim emergency guidance]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>with organ dysfunction</th>
<th>plus</th>
<th>supportive care</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Multi-organ dysfunction is a common feature of advanced infection and includes acute kidney</td>
</tr>
<tr>
<td>Patient group</td>
<td>Tx line</td>
<td>Treatment</td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>Acute</td>
<td></td>
<td>injury, pancreatitis, adrenal failure, and liver damage.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Liver damage (e.g., hepatitis) is common; however, jaundice is not a common feature. [59]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Renal dysfunction is common in the advanced stages, but can be reversed with adequate fluid resuscitation in the initial stages. [59] In patients with anuria who do not respond to fluid resuscitation, renal replacement therapy has been used, although there are no trial data to support the efficacy of this intervention. Of the 5 critically ill patients in Europe and North America with multi-organ failure who were managed with both invasive mechanical ventilation and renal replacement therapy, 3 died. [36] [92] [114] [116] [135]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Major bleeding occurs infrequently, but is a manifestation of advanced infection that is usually fatal. When available, platelet and plasma transfusions should be given according to local protocols. [134]</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>platelet/plasma transfusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Malaria should be tested for and treated with appropriate antimalarial therapy if present while keeping in mind the patient's risk for Ebola virus infection and the possibility of a dual infection. In endemic settings, malaria treatment is usually given as part of the routine management protocol, with or without confirmation of the infection.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» [Centers for Disease Control and Prevention (CDC): recommendations for managing and preventing cases of malaria in areas with Ebola]</td>
</tr>
<tr>
<td></td>
<td>plus</td>
<td>antimalarial therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» The general medical management of pregnant women is the same as for any other person who is infected.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Intrapartum haemorrhage and spontaneous abortion appear to be common in infected women; therefore, obstetric management should focus on monitoring for, and early treatment of, haemorrhagic complications. [21] [141] [142] [143] [144] Experience during the 2014 outbreak</td>
</tr>
</tbody>
</table>
Acute

<table>
<thead>
<tr>
<th>Patient group</th>
<th>Tx line</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>suggests that good outcomes can occasionally be achieved. [145]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Recommendations for PPE use by healthcare workers caring for pregnant women are the same as for healthcare workers caring for non-pregnant adults.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» There are no data available to recommend one delivery method over another. Infected women or women with suspected infection are advised not to breastfeed unless breast milk has been shown to be PCR negative for Ebola virus.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Amniotic fluid has been shown to contain the virus, including when the level was found to be undetectable in blood. Therefore recommendations for delivery include avoiding the induction of labour, particularly rupturing of membranes. [145]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» The WHO and CDC have produced specific guidance for caring for pregnant women: [World Health Organization (WHO): Ebola virus disease in pregnancy: screening and management of Ebola cases, contacts and survivors] [Centers for Disease Control and Prevention (CDC): guidance for screening and caring for pregnant women with Ebola virus disease for healthcare providers in US hospitals]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» Public Health England (PHE) have also produced guidance: [Public Health England (PHE): Ebola in pregnancy - information for healthcare workers]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>» The CDC has also produced specific guidance for caring for neonates born to infected women: [Centers for Disease Control and Prevention (CDC): care of a neonate born to a mother who is confirmed to have Ebola, is a person under investigation, or has been exposed to Ebola]</td>
</tr>
</tbody>
</table>
Emerging

Experimental therapies

Experimental treatments for Ebola virus infection are under development; however, they have not yet been fully tested for safety or effectiveness.[146] [147] [148] As this is a rapidly developing area, the latest World Health Organization (WHO) guidance should be consulted. [World Health Organization (WHO): Ebola R&D landscape of clinical candidates and trials] The US Food and Drug Administration (FDA) is working to help expedite the development and availability of medical products. [US Food and Drug Administration: Ebola response updates from FDA]

Vaccines

No vaccines have been licensed for use in humans.[70] [World Health Organization (WHO): Ebola vaccines, therapies, and diagnostics] rVSV-ZEBOV (also known as rVSV-ZEBOV-GP or V920) is a live attenuated vesicular stomatitis virus with 1 of its genes replaced by an Ebola virus gene. Phase I trials have confirmed the safety of this vaccine, although joint pain seems to be a common, self-limiting adverse effect.[71] [72] [73] [149] The STRIVE (Sierra Leone Trial to Introduce a Vaccine against Ebola) trial is a combined phase II and III clinical trial to assess the safety and efficacy of rVSV-ZEBOV, and is currently being conducted in Sierra Leone. [Centers for Disease Control and Prevention (CDC): Sierra Leone trial to introduce a vaccine against Ebola (STRIVE) Q&A] An open-label, cluster-randomised, ring vaccination trial in which contacts of a suspected Ebola case were vaccinated with a single intramuscular dose of rVSV-ZEBOV was conducted in Guinea. Patients in the treatment arm received the vaccine immediately, while vaccination was delayed by 21 days in the control arm. The study found that rVSV-ZEBOV has a high protective efficacy. No patients who received the vaccine developed Ebola virus infection 10 days or more after randomisation in the immediate-treatment arm; however, cases occurred in unvaccinated patients in the comparison group.[74] The vaccine has been granted PRIME status by the European Medicines Agency and Breakthrough Therapy Designation by the FDA. Another vaccine candidate, which uses a prime-boost strategy to enhance immunogenicity and involves the use of 2 distinct viral vectors that are administered as different doses (Ad26-EBOV and MVA-EBOV), has undergone phase I clinical trials in the UK.[75] [76] A number of other vaccine candidates are in the development pipeline, including a recombinant protein vaccine undergoing phase I trials in Australia. ChAd3-ZEBOV is a chimpanzee-derived adenovirus vector with an Ebola virus gene inserted. Phase II and III trials are in progress.[77] [World Health Organization (WHO): Ebola vaccines, therapies, and diagnostics]

Favipiravir

Formerly known as T-705, favipiravir is an experimental antiviral drug that selectively inhibits viral RNA-dependent RNA polymerase. It is active against influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus, as well as other flaviviruses, arenaviruses, bunyaviruses, and alphaviruses. The drug is currently approved in Japan for influenza pandemics, but has been found to be effective against Ebola virus in mouse models.[150] Human phase II trials in Guinea used a higher dose than that used for influenza. The JIKI trial, a multi-centre non-randomised trial undertaken in Guinea in 2014-2015, suggested good tolerability at a higher dose in a low-resource setting, as well as a potential benefit in patients with low viral loads.[151]

TKM-100802 (siRNA)

Also known as TKM-Ebola. Consists of a combination of small interfering RNAs that target Ebola virus RNA polymerase-L, formulated with lipid nanoparticle technology. Has been shown to be protective in non-human primates, and is effective against Marburg virus in guinea pigs and monkeys.[152] [153] [154] [155] The US Food and Drug Administration (FDA) granted expanded access use of this drug under an Investigational New Drug application (IND). Using emergency protocols, it was administered to a small number of patients.[136] [146] However, a phase II single-arm trial started in Sierra Leone in March 2015 was discontinued in June 2015, after 19 patients were enrolled, due to a lack of clinical benefit.[156]

ZMapp
An experimental combination of 3 humanised monoclonal antibodies targeted at 3 Ebola virus glycoprotein epitopes, engineered for expression in tobacco plants.[146] ZMapp had been found to be protective when administered to non-human primates 24 to 48 hours after infection. Another study showed that the drug was able to rescue non-human primates when treatment is initiated up to 5 days after infection.[158] A randomised, controlled trial in 72 patients in sites in Liberia, Sierra Leone, Guinea, and the US found that, although the use of ZMapp plus the current standard of care appeared to be beneficial compared with current standard care alone, results did not meet the pre-specified statistical threshold for efficacy and further research is required.[159] No major safety concerns were noted in this trial, and only one serious adverse effect (hypertension) was found to be related to the infusion itself.

ZMab
An experimental product composed of 3 monoclonal antibodies directed against the envelope glycoproteins of the Ebola virus, developed by the National Microbiology Laboratory (Winnipeg, Canada), through the Public Health Agency of Canada. Not made to good manufacturing practice (GMP) standards, it has been used in some patients on a compassionate basis. Concerns have been raised by reports of the rapid emergence of resistant Ebola virus mutants in primates with delayed death after treatment with monoclonal antibody preparations, emphasising the importance of detailed monitoring of any patients treated with these products.[160]

MIL-77
Contains 3 monoclonal antibodies prepared in China in mammalian Chinese hamster ovary (CHO) cell-line cultures. This experimental preparation has been used on a compassionate basis in two British patients who both survived.[161]

BCX-4430
An experimental adenosine analogue found to be active against Ebola virus in rodents. Its mechanism of action is thought to be due to the inhibition of viral RNA-dependent RNA polymerase. It is active against flaviviruses, bunyaviruses, arenaviruses, and paramyxoviruses. The drug has been shown to be protective in non-human primates and rodents, even when administered 48 hours after infection.[162] A phase I safety trial is under way.

FX06
One severely unwell patient in Germany was successfully given 3 doses of FX06, a fibrin-derived peptide, in addition to renal replacement therapy and high-quality intensive care.[114] This drug is currently being evaluated as a potential adjunctive treatment for sepsis with vascular leak syndrome in animal models. It has also been evaluated in humans as a potential treatment for preventing reperfusion injury after cardiac revascularisation with no major negative adverse effects.[163] [164] It has been given on a compassionate-use basis to 2 patients; however, no conclusions can be drawn yet.

AVI-7537
A drug consisting of antisense phosphorodiamidate morpholino oligomers (PMOs) that target the Ebola virus VP24 gene. It has been shown to confer a survival benefit to infected non-human primates.[165] AVI-6002 is an experimental drug that consists of 2 PMOs (AV-7537, and AV-7539, which targets the VP35 gene). AV-6002 has undergone phase I clinical studies.[136] [146] [166]

GS-5734
A prodrug of adenine nucleotide analogue that has potent activity against a variety of filoviruses in primate cell infection models. Initial studies have demonstrated excellent effectiveness as a treatment in non-human primates infected with Ebola virus.[167] It was used in the UK for a case of late Ebola virus relapse with meningoencephalitis. The patient recovered after being treated with a 14-day course given in combination with a high-dose corticosteroid. This appears to be a promising agent for further studies.
Interferons

Interferons have been used in the past but have unproven efficacy.[136] A phase II study is under way with limited patient enrolment to date.

Brincidofovir

Formerly known as CMX-001, brincidofovir is an experimental antiviral drug currently undergoing phase III trials for the treatment of cytomegalovirus and adenovirus. It also shows activity against Ebola virus in vitro.[136] [146] [168] The manufacturer announced that it would no longer participate in clinical trials of the drug for the treatment of Ebola owing to the decline of new cases of infection in Liberia, and the drug has been deprioritised for use in Ebola treatment.[169]

Other drugs

Therapeutic agents used for other diseases, such as clomifene, and chloroquine, inhibit Ebola virus interactions with human cells in models, but no trials are currently registered. Amiodarone has been shown to inhibit filovirus cell entry, and has been used compassionately in one treatment facility in Sierra Leone.[147] [170] [171] Atorvastatin plus irbesartan with or without clomifene has been used to treat some patients in Sierra Leone; however, no clinical data are available. Aptamers (DNA or RNA molecules selected in vitro and capable of binding a wide range of nucleic and non-nucleic acid molecules with high affinity and specificity) are being studied for the treatment of Ebola virus infection.[172] Small molecule inhibitors of Ebola virus infection are also being studied.[173] WHO has prioritised the antimalarial drug amodiaquine for testing in non-human primates. A specifically configured, experimental RNA compound, rintatolimod, has shown positive results against Ebola in an animal model.
Recommendations

Monitoring

There are no specific requirements for monitoring after discharge; however, eligible patients may be asked to donate blood from 28 days after the date of discharge to be used in the treatment of patients with active infection.[192]

Patient instructions

Education:

- A fact sheet is available from the Centers for Disease Control and Prevention (CDC). [Centers for Disease Control and Prevention (CDC): questions and answers - 2014 Ebola outbreak]
- Bushmeat from Africa should not be imported into other countries. [Centers for Disease Control and Prevention (CDC): facts about bushmeat and Ebola]
- Household pets are not thought to be at significant risk for infection. [Centers for Disease Control and Prevention (CDC): questions and answers about Ebola, pets, and other animals] [World Health Organization (WHO): Ebola virus disease and household pets]
- Patients should be educated about the likely course of convalescence and the possibility of long-term complications.

Sexual health:

- The WHO provides guidance on safe sex practices for survivors and their partners. [World Health Organization (WHO): interim advice on the sexual transmission of the Ebola virus disease]
- Women should be advised not to breastfeed during infection,[39] unless breast milk has been shown to be PCR negative for Ebola virus.
- The WHO recommends that men should be offered semen testing from 3 months after symptom onset and be abstinent or use condoms until two negative semen tests (or at least 6 months after resolution of symptoms).[47]

Travel:

- The WHO and CDC produce guidance for travellers. [World Health Organization (WHO): travel and transport risk assessment] [Centers for Disease Control and Prevention (CDC): Ebola - travel notices]

Complications

<table>
<thead>
<tr>
<th>Complications</th>
<th>Timeframe</th>
<th>Likelihood</th>
</tr>
</thead>
<tbody>
<tr>
<td>acute kidney injury</td>
<td>short term</td>
<td>high</td>
</tr>
</tbody>
</table>

Frequent in severe disease. May be caused by dehydration initially, but may be a consequence of disseminated intravascular coagulation or direct damage to the kidneys by the Ebola virus in later stages.[17] [59] [81] Early recognition by monitoring urine output and blood biochemistry enables prompt action to be taken.
Aetiology in Ebola virus infection is still not well understood. Multiple factors may contribute, including: bacterial sepsis, possibly through gut translocation of bacteria; a direct effect of the virus; disseminated intravascular coagulation; and haemorrhage. Management follows the same principles as for bacterial sepsis.

Disseminated intravascular coagulation

Predisposes patient to bleeding complications. Major bleeding occurs infrequently, but is a manifestation of advanced infection that is usually fatal. When available, platelet and plasma transfusions should be given according to local protocols.

Miscarriage/maternal death

Pregnant women have a high incidence of miscarriage, and infection is frequently fatal in these women.

Late convalescence complications

Patients who survive commonly exhibit a protracted recovery characterised by asthenia, weight loss, and migratory arthralgia. Skin desquamation and transient hair loss also occur frequently.

Late manifestations during convalescence are uncommon but may include orchitis, myelitis, parotitis, pancreatitis, hepatitis, psychosis, and hearing loss/tinnitus. Survivors are also at risk of uveitis (anterior, posterior, or panuveitis), which may lead to secondary structural complications, vision impairment, or blindness. One retrospective, uncontrolled, cross-sectional study found that approximately 28% of survivors developed Ebola-associated uveitis, and 3% developed Ebola-associated optic neuropathy. In patients with uveitis, 38.5% of patients were blind. One survivor had acute uveitis with detection of viable Ebola virus 14 weeks after the onset of infection and 9 weeks after the clearance of the virus from the blood. One expatriate healthcare worker presented with Ebola virus meningoencephalitis (RT-PCR of CSF and plasma were positive for Ebola virus) 9 months after recovering from severe primary Ebola virus disease in 2015.

The aetiology of these manifestations is unclear but could be related to immune complex phenomena or the persistence of Ebola virus in immune-privileged sites.

Prognosis

The natural clinical course of Ebola virus infection varies markedly between the different viral species and according to the level of supportive medical care available. The most lethal species is Zaire ebolavirus, which has a reported case fatality rate of up to 90%. The rate in the 2014 outbreak was estimated to be around 50%, although collecting accurate data was not possible due to poor record keeping. Most epidemics have taken place in resource-poor settings that have little supportive care; therefore, the case fatality rate in other settings could be <40%.

Younger children (<5 years of age) and adults over 40 years of age have a higher mortality rate compared with adolescents and younger adults. Women have a slightly better survival rate compared with men.
High viral load, acute kidney injury, and neurological involvement are also predictors of poor outcome.[3] [5] [20] [21] [22] [87] [88] [97] [122] [123] [124]

An observational study from an outbreak in 1995 showed a marked decrease in the case fatality rate from 93% to 69% between the initial and final phases of the outbreak.[176] This suggests that later cases were recognised earlier, and possibly received higher quality of care.

Pregnant women have a high incidence of miscarriage, and infection is frequently fatal in these women.[21] [141] [142] [143]

Data on the effects of HIV infection on prognosis are being awaited. One study suggests that infection with GB virus C, an immunomodulatory pegivirus that is present in up to 28% of West Africans, is associated with better survival from acute Ebola virus disease.[177]

### Infection course

Patients who die tend to develop clinical signs early on in the infection, with death usually attributed to shock and multi-organ failure, typically occurring between days 6 and 16 of infection.[5] [14] [15] [16] Patients who eventually recover exhibit isolated fever for several days with improvement typically around days 6 to 11.[97]

### Prognostic indicators

Observational studies have shown that patients with fatal disease develop advanced features of infection (e.g., prostration, obtundation, hypotension, neurological involvement) earlier in the course of infection compared with patients who survived with an observed median survival of 9 days from symptom onset.[5] [14] Acute kidney injury and higher viral load both correlate with adverse outcome and increased mortality.[20] [21] [22] [93] [95] Biomarkers as prognostic indicators require further study.[14] [81] [97]

### Recovery and convalescence

Patients who live through the second week of infection have a >75% chance of surviving.[17] Patients are usually discharged from the isolation facility when they are ambulant, self-caring, lack significant symptoms (e.g., diarhoea, vomiting, bleeding), and have 2 negative reverse transcriptase-polymerase chain reaction (RT-PCR) results for Ebola virus taken 48 hours apart.[93] Viral shedding in seminal fluid may continue for more than a year and a half after recovery.[39] [40] [41] [42] [43] [44] [46] [47] [178] [179] The virus was detected in semen in 65% of men 4 to 6 months after recovery from acute infection.[42] Another study found that 63% of men tested positive for the virus in their semen 12 months or longer after recovery, with the longest interval between discharge from a treatment unit and sample collection being 565 days.[178] It has also been detected in semen for up to 548 days after disease onset in 5% of men.[179] Sexual transmission of the virus from a man to his sexual partner has been confirmed by genomic studies in Liberia.[45] Ebola virus has also been detected in vaginal fluid.[48] The World Health Organization (WHO) recommends that men should be offered semen testing from 3 months after symptom onset and be abstinent or use condoms until two negative semen tests (or at least 6 months after resolution of symptoms).[47] [178] Virus has been detected in sweat (up to day 40), urine (up to day 30), conjunctival fluid (up to day 22), faeces (up to day 19), and breast milk (up to day 17), even in the absence of viraemia.[180]

Patients who survive commonly exhibit a protracted recovery characterised by arthralgias (76% to 77%), fatigue (69%), ocular symptoms (14% to 60%), headache (48% to 54%), abdominal pain (54%), anaemia (50%), skin disorders (49%), and auditory symptoms (24%).[181] [182] [183]

Late manifestations during convalescence may include orchitis, myelitis, parotitis, pancreatitis, hepatitis, and psychosis.[18] Survivors are also at risk of uveitis (anterior, posterior, or panuveitis), which may lead to secondary structural complications, vision impairment, or blindness.[184] One retrospective, uncontrolled, cross-sectional study found that approximately 28% of survivors developed Ebola-associated uveitis, and 3% developed Ebola-associated optic neuropathy. In patients with uveitis, 38.5% of patients were found to be blind (visual acuity >20/400).[185] One survivor had acute uveitis with detection of viable Ebola virus 14 weeks after the onset of infection and 9 weeks after the clearance of the virus from the blood.[186] [187] Unilateral white cataracts and a novel retinal lesion following the anatomical distribution of the optic nerve axons have also been reported.[188] The aetiology of these manifestations is unclear but could be related to
immune complex phenomena or the persistence of Ebola virus in immune-privileged sites. Regular check-ups of survivors are recommended for at least 18 months after recovery.[179]

It is likely that survivors of infection acquire lifetime immunity to the same strain of Ebola virus. As a consequence of this, patients who have recovered from infection have been invaluable in caring for patients with active infections. However, our understanding of viral persistence in sanctuary sites remains incomplete. One expatriate healthcare worker presented with Ebola virus meningoencephalitis (RT-PCR of CSF and plasma were positive for Ebola virus) 9 months after recovering from severe primary Ebola virus disease in 2015.[189] There are a few anecdotal reports of such presentations in the 2014 outbreak countries, but these are not common. The possibility of prolonged persistence and late re-emergence of clinical disease will probably alter the epidemiological and clinical approach to survivors who present with subsequent illnesses. This is also a theoretical concern for the management of women who become pregnant soon after recovery from acute Ebola infection.

Survivors and orphans of those who have died face stigma and ostracism in many communities. This can be associated with psychological issues.[190] [191]
# Diagnostic guidelines

## Europe

**Ebola virus disease: screening and testing activity**

**Published by:** Public Health England (PHE)  
**Last published:** 2016  
**Summary:** Provides information on the number of individuals screened at ports across England and the total number of Ebola-related tests carried out since the start of the outbreak.

**Viral haemorrhagic fever: sample testing advice**

**Published by:** Public Health England (PHE)  
**Last published:** 2016  
**Summary:** Gives instructions about the procedure for diagnostic testing in the UK. Outlines the packaging and transport of samples. Provides useful links and contacts.

## International

**Implementation and management of contact tracing for Ebola virus disease**

**Published by:** World Health Organization (WHO); Centers for Disease Control and Prevention (CDC)  
**Last published:** 2015  
**Summary:** This guideline provides a comprehensive overview of contact tracing in the Ebola response.

**Interim guidance on the use of rapid Ebola antigen detection tests**

**Published by:** World Health Organization (WHO)  
**Last published:** 2015  
**Summary:** Provides guidance on the potential use of available rapid Ebola antigen-detection tests.

**How to safely ship human blood samples from suspected Ebola cases within a country by road, rail, and sea**

**Published by:** World Health Organization (WHO)  
**Last published:** 2014  
**Summary:** Steps on how to safely ship human blood samples within a country.

**Exit screening at airports, ports and land crossings: interim guidance for Ebola virus disease**

**Published by:** World Health Organization (WHO)  
**Last published:** 2014  
**Summary:** Information to assist countries in developing exit screening plans and standard operating procedures.

**Laboratory diagnosis of Ebola virus disease: interim guideline**

**Published by:** World Health Organization (WHO)  
**Last published:** 2014  
**Summary:** Provides advice on specimen collection and timing. Outlines biosafety levels required in the laboratory. Instructions on appropriate shipping of samples.
## International

### Travel and transport risk assessment: Ebola - interim guidance for public health authorities and the transport sector

**Published by:** World Health Organization (WHO)  
**Last published:** 2014  
**Summary:** Provides information for travellers to and from Ebola-affected countries.

### Infection prevention and control (IPC) guidance summary: Ebola guidance package

**Published by:** World Health Organization (WHO)  
**Last published:** 2014  
**Summary:** Provides a summary of measures for those providing direct and non-direct care to patients with suspected or confirmed Ebola virus disease.

## North America

### Guidance for U.S. laboratories for managing and testing routine clinical specimens when there is a concern about Ebola virus disease

**Published by:** Centers for Disease Control and Prevention (CDC)  
**Last published:** 2015  
**Summary:** Guidance for the management and evaluation of routine clinical specimens for differential testing and diagnoses other than Ebola virus disease.

### Guidance for collection, transport and submission of specimens for Ebola virus testing

**Published by:** Centers for Disease Control and Prevention (CDC)  
**Last published:** 2015  
**Summary:** Provides advice on safe handling of specimens, processing samples from suspected patients, and storage, packaging, and transport of diagnostic specimens.

## Treatment guidelines

### Europe

### Ebola response anthropology platform

**Published by:** Institute of Development Studies; University of Sussex; University of Exeter; London School of Hygiene and Tropical Medicine  
**Last published:** 2016  
**Summary:** Anthropologists from around the world providing advice on how to engage with crucial socio-cultural and political dimensions of the Ebola outbreak and build locally appropriate interventions.
## Guidelines

### Europe

**Management of hazard group 4 viral haemorrhagic fevers and similar human infectious diseases of high consequence**

*Published by:* Public Health England (PHE) Advisory Committee on Dangerous Pathogens  
*Last published:* 2015  
*Summary:* Targets healthcare settings within UK hospitals. Patient risk assessment algorithm based on the WHO guideline. Detailed documents on infection control, waste management, and laboratory containment.

**Ebola virus disease: clinical management and guidance**

*Published by:* Public Health England (PHE)  
*Last published:* 2015  
*Summary:* Links to all guidance offered by PHE on Ebola virus infection.

**Guidance paper Ebola Treatment Centre (ETC): pregnant & lactating women**

*Published by:* Royal College of Obstetricians and Gynaecologists  
*Last published:* 2014  
*Summary:* Guidance paper for pregnant and lactating women.

**Ebola guidance for emergency departments**

*Published by:* The College of Emergency Medicine; Public Health England (PHE)  
*Last published:* 2014  
*Summary:* Guidance to assist all staff working in emergency departments in the UK and Ireland.

**Safe use of personal protective equipment in the treatment of infectious diseases of high consequence**

*Published by:* European Centre for Disease Prevention and Control (ECDC)  
*Last published:* 2014  
*Summary:* Tutorial that presents the fundamental concepts of personal protective equipment (PPE) and barrier nursing to support preparedness in hospitals across Europe. It provides practical information on the proper use of PPE at the point of care, including technical requirements and procurement aspects.

**Public health management of healthcare workers returning from Ebola-affected areas**

*Published by:* European Centre for Disease Prevention and Control (ECDC)  
*Last published:* 2014  
*Summary:* Technical report with proposed measures for the management of healthcare workers returning from affected areas.

**Public health management of persons having had contact with Ebola virus disease cases in the EU**

*Published by:* European Centre for Disease Prevention and Control (ECDC)  
*Last published:* 2014  
*Summary:* Provides guidance to European public health authorities for the management of those having had contact with Ebola virus disease cases.
### Europe

**Assessing and planning medical evacuation flights to Europe for patients with Ebola virus disease and people exposed to Ebola virus**

**Published by:** European Centre for Disease Prevention and Control (ECDC)  
**Last published:** 2014

**Summary:** Aims to guide decision-making when there is a perceived need for medical evacuation by air of an Ebola-infected or Ebola-exposed person from an Ebola-affected country to an EU Member State.

### Infection prevention and control measures for Ebola virus disease: entry and exit screening measures

**Published by:** European Centre for Disease Prevention and Control (ECDC)  
**Last published:** 2014

**Summary:** Details the existing evidence on entry and exit screening in order to support decision making by European public health authorities.

### International

**Clinical care for survivors of Ebola virus disease**

**Published by:** World Health Organization (WHO)  
**Last published:** 2016

**Summary:** Interim guidance to guide health services on how to provide care for survivors.

**Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker**

**Published by:** World Health Organization (WHO)  
**Last published:** 2016

**Summary:** The purpose of this pocketbook is to provide clear guidance on current best management practices for viral haemorrhagic fever across healthcare facilities.

**Ebola virus disease in pregnancy: screening and management of Ebola cases, contacts and survivors**

**Published by:** World Health Organization (WHO)  
**Last published:** 2015

**Summary:** Provides a comprehensive overview of screening and management of Ebola virus disease in pregnancy.

**Guidance for immunization programmes in the African Region in the context of Ebola**

**Published by:** World Health Organization (WHO)  
**Last published:** 2015

**Summary:** This document aims to assist countries to: maintain and/or restart immunisation services; continue to disseminate educational and social mobilisation messages and contribute to Ebola surveillance; and provide guidance on infection prevention and control during vaccination.
# International

## Rapid guidance on the decommissioning of Ebola care facilities

**Published by:** World Health Organization (WHO)  
**Last published:** 2015  
**Summary:** This guidance pertains to protecting the safety and repurposing of infrastructures and resources previously used for the Ebola outbreak to care for Ebola patients.

## Manual for the care and management of patients in Ebola care units/community care centres - interim emergency guidance

**Published by:** World Health Organization (WHO)  
**Last published:** 2015  
**Summary:** Provides guidance on best practices to be followed in Ebola care units/community care centres, intended for health aid workers and others providing care for patients. Provides many useful charts and tables including paediatric doses and fluid and nutrition regimens. The care of patients with other causes of fever is also described.

## Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks

**Published by:** World Health Organization (WHO)  
**Last published:** 2014  
**Summary:** Interim guidance to national health authorities and blood transfusion services that outlines the steps required to collect convalescent whole blood or plasma from patients who have recovered from Ebola virus infection for transfusion to patients with early Ebola virus infection as an empirical treatment modality.

## Filovirus haemorrhagic fever guideline

**Published by:** Medecins Sans Frontieres  
**Last published:** 2008  
**Summary:** Caters for the needs of clinicians working in resource-poor settings. Comprehensive information on setting up and managing a treatment centre. Algorithms explaining patient care and the management of complications. Logistical advice on organising the public health aspect of infection, including burials.

# North America

## Yellow book chapter 3 - infectious diseases related to travel: Ebola virus disease and Marburg virus disease

**Published by:** Centers for Disease Control and Prevention (CDC)  
**Last published:** 2017  
**Summary:** Describes the viruses and their transmission, and gives recommendations on diagnosis and management of the diseases.

## Yellow book chapter 3 - infectious diseases related to travel: viral hemorrhagic fevers

**Published by:** Centers for Disease Control and Prevention (CDC)  
**Last published:** 2017  
**Summary:** Describes the viruses and their transmission, and gives recommendations on diagnosis and management of the diseases.
### North America

#### Interim guidance for management of survivors of Ebola virus disease in U.S. healthcare settings

**Published by:** Centers for Disease Control and Prevention (CDC)  
**Last published:** 2016  
**Summary:** Provides information about sequelae and Ebola virus persistence in survivors, as well as infection prevention and control recommendations for US healthcare providers when evaluating survivors.

#### Ebola virus disease information for clinicians in U.S. healthcare settings

**Published by:** Centers for Disease Control and Prevention (CDC)  
**Last published:** 2016  
**Summary:** Provides an overview of the disease targeted at clinicians working in the US and includes links to other documents outlining assessment, investigation, management, and infection control.

#### Guidance on personal protective equipment to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation for Ebola who are clinically unstable or have bleeding, vomiting, or diarrhea in U.S. hospitals, including procedures for donning and doffing PPE

**Published by:** Centers for Disease Control and Prevention (CDC)  
**Last published:** 2015  
**Summary:** Detailed guidance on the types of personal protective equipment (PPE) to be used and on the processes for donning and doffing (i.e., putting on and removing) PPE for all healthcare workers entering the room of a patient hospitalised with Ebola virus infection.

#### Interim guidance for U.S. hospital preparedness for patients under investigation (PUIs) or with confirmed Ebola virus disease (EVD): a framework for a tiered approach

**Published by:** Centers for Disease Control and Prevention (CDC)  
**Last published:** 2015  
**Summary:** Guidance to assist state and local health departments, acute care hospitals, and other emergency care settings develop preparedness plans for patients with possible Ebola virus infection.

#### Practice advisory: care of obstetric patients during an Ebola virus outbreak

**Published by:** American Congress of Obstetricians and Gynecologists (ACOG)  
**Last published:** 2014  
**Summary:** Recommendations for managing pregnant patients with suspected or confirmed infection.

#### Ebola clinical care guidelines

**Published by:** Canadian Critical Care Society  
**Last published:** 2014  
**Summary:** Targets healthcare settings within Canadian hospitals. Detailed guidelines for the clinical care of patients with Ebola virus infection, including invasive and non-invasive monitoring, body fluid control, airway management fluid resuscitation and electrolytes, organ support, symptom management, experimental therapies, and palliative care.
## Asia

**Infection prevention and control guidelines for Ebola virus disease (EVD)**

**Published by:** Ministry of Health (Sultanate of Oman)  
**Last published:** 2014  
**Summary:** Outlines preventive measures issued by the Ministry of Health in Oman. Includes fatwa (religious opinion) on washing and burying deceased bodies.

## Oceania

**Ebolavirus disease information for clinicians**

**Published by:** Department of Health (Australia)  
**Last published:** 2014  
**Summary:** Summary of guidance in Australia.
Online resources

1. World Health Organization (WHO): Ebola virus disease (external link)
2. Centers for Disease Control and Prevention (CDC): Ebola (Ebola virus disease) (external link)
3. World Health Organization (WHO): Democratic Republic of Congo external situation report (external link)
5. Centers for Disease Control and Prevention (CDC): Ebola transmission (external link)
6. Centers for Disease Control and Prevention (CDC): epidemiologic risk factors to consider when evaluating a person for exposure to Ebola virus (external link)
7. World Health Organization (WHO): aide-memoire for infection prevention and control in a health care facility (external link)
8. Centers for Disease Control and Prevention (CDC): infection control for viral haemorrhagic fevers in the African health care setting (external link)
9. Centers for Disease Control and Prevention (CDC): the buddy system (external link)
10. World Health Organization (WHO): personal protective equipment in the context of Filovirus disease outbreak response - rapid advice guideline (external link)
11. World Health Organization (WHO): steps to put on personal protective equipment (PPE) (external link)
12. World Health Organization (WHO): steps to remove personal protective equipment (PPE) (external link)
13. Centers for Disease Control and Prevention (CDC): guidance on personal protective equipment (PPE) to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation (PUIs) for Ebola (external link)
14. Centers for Disease Control and Prevention (CDC): Sierra Leone trial to introduce a vaccine against Ebola (STRIVE) Q&A (external link)
15. World Health Organization (WHO): Ebola vaccines, therapies, and diagnostics (external link)
17. Centers for Disease Control and Prevention (CDC): Ebola prevention (external link)
18. World Health Organization (WHO): infection prevention and control (IPC) guidance summary (external link)


20. World Health Organization (WHO): case definition recommendations for Ebola or Marburg virus diseases (external link)


22. World Health Organization (WHO): how to safely collect blood samples from persons suspected to be infected with highly infectious blood-borne pathogens (external link)

23. Centers for Disease Control and Prevention (CDC): guidance for collection, transport and submission of specimens for Ebola virus testing (external link)

24. Centers for Disease Control and Prevention (CDC): guidance for US laboratories for managing and testing routine clinical specimens when there is a concern about Ebola virus disease (external link)

25. World Health Organization (WHO): interim guidance on the use of rapid Ebola antigen detection tests (external link)

26. Food and Drug Administration (FDA): 2014 Ebola virus emergency use authorizations (external link)

27. World Health Organization (WHO): clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker (external link)

28. Centers for Disease Control and Prevention (CDC): Ebola diagnosis (external link)


30. World Health Organization (WHO): Ebola surveillance in countries with no reported cases of Ebola virus disease (external link)


32. Centers for Disease Control and Prevention (CDC): guidance for screening and caring for pregnant women with Ebola virus disease for healthcare providers in US hospitals (external link)


34. World Health Organization (WHO): manual for the care and management of patients in Ebola care units/community care centres - interim emergency guidance (external link)
<table>
<thead>
<tr>
<th></th>
<th>Online resources</th>
</tr>
</thead>
<tbody>
<tr>
<td>35.</td>
<td>World Health Organization (WHO): use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks <em>(external link)</em></td>
</tr>
<tr>
<td>36.</td>
<td>World Health Organization (WHO): ethics of using convalescent whole blood and convalescent plasma during the Ebola epidemic <em>(external link)</em></td>
</tr>
<tr>
<td>37.</td>
<td>Centers for Disease Control and Prevention (CDC): recommendations for managing and preventing cases of malaria in areas with Ebola <em>(external link)</em></td>
</tr>
<tr>
<td>38.</td>
<td>Centers for Disease Control and Prevention (CDC): care of a neonate born to a mother who is confirmed to have Ebola, is a person under investigation, or has been exposed to Ebola <em>(external link)</em></td>
</tr>
<tr>
<td>39.</td>
<td>World Health Organization (WHO): Ebola R&amp;D landscape of clinical candidates and trials <em>(external link)</em></td>
</tr>
<tr>
<td>40.</td>
<td>Centers for Disease Control and Prevention (CDC): Ebola treatment <em>(external link)</em></td>
</tr>
<tr>
<td>41.</td>
<td>US Food and Drug Administration: Ebola response updates from FDA <em>(external link)</em></td>
</tr>
<tr>
<td>42.</td>
<td>World Health Organization (WHO): Ebola virus disease fact sheet <em>(external link)</em></td>
</tr>
<tr>
<td>43.</td>
<td>Centers for Disease Control and Prevention (CDC): questions and answers - 2014 Ebola outbreak <em>(external link)</em></td>
</tr>
<tr>
<td>44.</td>
<td>Centers for Disease Control and Prevention (CDC): facts about bushmeat and Ebola <em>(external link)</em></td>
</tr>
<tr>
<td>45.</td>
<td>Centers for Disease Control and Prevention (CDC): questions and answers about Ebola, pets, and other animals <em>(external link)</em></td>
</tr>
<tr>
<td>46.</td>
<td>World Health Organization (WHO): Ebola virus disease and household pets <em>(external link)</em></td>
</tr>
<tr>
<td>47.</td>
<td>World Health Organization (WHO): interim advice on the sexual transmission of the Ebola virus disease <em>(external link)</em></td>
</tr>
<tr>
<td>48.</td>
<td>World Health Organization (WHO): travel and transport risk assessment <em>(external link)</em></td>
</tr>
<tr>
<td>49.</td>
<td>Centers for Disease Control and Prevention (CDC): Ebola - travel notices <em>(external link)</em></td>
</tr>
<tr>
<td>50.</td>
<td>World Health Organization (WHO): implementation and management of contact tracing for Ebola virus disease <em>(external link)</em></td>
</tr>
<tr>
<td>51.</td>
<td>World Health Organization (WHO): how to conduct safe and dignified burial of a patient who has died from suspected or confirmed Ebola virus disease <em>(external link)</em></td>
</tr>
</tbody>
</table>
Key articles


References


Ebola virus infection


67. Strauss S. Ebola research fueled by bioterrorism threat. CMAJ. 2014;186:1206. Full text Abstract

68. Centers for Disease Control and Prevention. Guidance on personal protective equipment to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation for Ebola who are clinically unstable or have bleeding, vomiting, or diarrhea in US hospitals, including procedures for donning and doffing PPE. August 2015. http://www.cdc.gov/ (last accessed 19 July 2017). Full text


78. Fletcher TE, Brooks TJ, Beeching NJ. Ebola and other viral haemorrhagic fevers. BMJ. 2014;349:g5079. Full text Abstract


86. Glynn JR. Age-specific incidence of Ebola virus disease. Lancet. 2015;386;432. Full text Abstract


<table>
<thead>
<tr>
<th>Reference</th>
<th>Title</th>
</tr>
</thead>
</table>


<table>
<thead>
<tr>
<th>Number</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>168.</td>
<td>Gulland A. Clinical trials of Ebola therapies to begin in December. BMJ. 2014;349:g6827. <a href="#">Abstract</a></td>
</tr>
</tbody>
</table>


Ebola virus infection

Images

Figure 1: Transmission electron micrograph showing some of the ultrastructural morphology displayed by an Ebola virus virion

Centers for Disease Control and Prevention

Figure 2: Ebolavirus ecology showing enzootic and epizootic cycles

Centers for Disease Control and Prevention
**Figure 3:** Healthcare worker in personal protective equipment at an Ebola treatment centre in Sierra Leone, 2014

*From the personal collection of Chris Lane, MSc (Public Health England/World Health Organization); used with permission*

**Figure 4:** Diagnostic pathway for the work-up of suspected Ebola virus infection

*Produced by the BMJ Evidence Centre*
Figure 5: Cholera beds with central hole in mattress to manage patients with profuse diarrhoea at an Ebola treatment centre in West Africa, 2014

From the personal collection of Catherine F. Houlihan, MSc, MB ChB, MRCP, DTMH; used with permission
Figure 6: Multidisciplinary ward rounds at the Save The Children Ebola treatment centre in Kerrytown, Sierra Leone (Ministry of Health representative, Cuban Medical Brigade representative, and a UK clinician)

From the collection of Tom E. Fletcher, MBE, MBChB, MRCP, DTM&H; used with permission
**Figure 7: General conditions at an Ebola treatment centre in West Africa, 2014**

From the personal collection of Catherine F. Houlihan, MSc, MB ChB, MRCP, DTMH; used with permission

![Image of general conditions at an Ebola treatment centre](image1.png)

**Figure 8: Ward area at an Ebola treatment centre in West Africa, 2014**

From the personal collection of Chris Lane, MSc; used with permission

![Image of ward area at an Ebola treatment centre](image2.png)
Figure 9: Oral rehydration solution supplies at an Ebola treatment centre in West Africa, 2014
From the personal collection of Chris Lane, MSc; used with permission

Figure 10: Insertion of an intravenous line in an adult with Ebola virus disease (West Africa)
From the collection of Tom E. Fletcher, MBE, MBChB, MRCP, DTM&H; used with permission
Figure 11: Insertion of an intraosseous line in a critically-ill adult with Ebola virus disease (West Africa)

From the collection of Tom E. Fletcher, MBE, MBChB, MRCP, DTM&H; used with permission
Disclaimer

This content is meant for medical professionals situated outside of the United States and Canada. The BMJ Publishing Group Ltd (“BMJ Group”) tries to ensure that the information provided is accurate and up-to-date, but we do not warrant that it is nor do our licensors who supply certain content linked to or otherwise accessible from our content. The BMJ Group does not advocate or endorse the use of any drug or therapy contained within nor does it diagnose patients. Medical professionals should use their own professional judgement in using this information and caring for their patients and the information herein should not be considered a substitute for that.

This information is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any contraindications or side effects. In addition such standards and practices in medicine change as new data become available, and you should consult a variety of sources. We strongly recommend that users independently verify specified diagnosis, treatments and follow up and ensure it is appropriate for your patient within your region. In addition, with respect to prescription medication, you are advised to check the product information sheet accompanying each drug to verify conditions of use and identify any changes in dosage schedule or contraindications, particularly if the agent to be administered is new, infrequently used, or has a narrow therapeutic range. You must always check that drugs referenced are licensed for the specified use and at the specified doses in your region. This information is provided on an “as is” basis and to the fullest extent permitted by law the BMJ Group and its licensors assume no responsibility for any aspect of healthcare administered with the aid of this information or any other use of this information.

View our full Website Terms and Conditions.
Contributors:

// Authors:

**Nicholas J. Beeching, MA, BM BCh, FRCP, FRACP, FFTM RCPS (Glasg), DCH, DTM&H**
Senior Lecturer (Honorary Consultant)
Liverpool School of Tropical Medicine and Royal Liverpool University Hospital, Liverpool, UK
DISCLOSURES: NJB is an author of several references cited in this monograph. NJB is partially supported by the National Institute of Health Research Health Protection Unit in Emerging and Zoonotic Infections at the University of Liverpool and Public Health England. He is affiliated with the Liverpool School of Tropical Medicine. Views expressed in this monograph are those of the contributor and do not necessarily represent the official position of the National Health Service, the National Institute for Health Research, the Department of Health, or Public Health England.

**Manuel Fenech, MD, MRCP, DTM&H**
Specialist Trainee in Infectious Diseases
Royal Liverpool University Hospital, Liverpool, UK
DISCLOSURES: MF declares that he has no competing interests.

**Tom E. Fletcher, MBE, MBChB, MRCP, DTM&H**
Wellcome Trust/MoD Research Fellow
Liverpool School of Tropical Medicine, Liverpool, UK
DISCLOSURES: TEF is an author of a number of references cited in this monograph. TEF is a consultant to the World Health Organization, and is funded by the UK Surgeon General and the Wellcome Trust.

**Catherine F. Houlihan, MSc, MB ChB, MRCP, DTM&H**
Clinical Lecturer
University College London, London, UK
DISCLOSURES: CFH declares that she has no competing interests.

// Acknowledgements:

Dr Nicholas J. Beeching, Dr Manuel Fenech, Dr Tom E. Fletcher, and Dr Catherine F. Houlihan would like to thank Dr Colin Brown (Infectious Disease Lead, Kings Sierra Leone Partnership) for his helpful comments and insights. CB declares that he has no competing interests.

// Peer Reviewers:

**William A. Petri, Jr, MD, PhD, FACP**
Wade Hampton Frost Professor of Epidemiology
Professor of Medicine, Microbiology, and Pathology, Chief, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA
DISCLOSURES: WAP declares that he has no competing interests.

**Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA**
Professor of Medicine and Epidemiology
UT Health Medical School, Medical Director of Epidemiology, Memorial Hermann Texas Medical Center, Houston, TX
Contributors:

DISCLOSURES: LO-Z declares that he has no competing interests.

**Stephen Mepham, MRCP (UK), FRCPATH, DTM&H, MD**

Consultant in Microbiology and Infectious Diseases
Royal Free London NHS Foundation Trust, London, UK
DISCLOSURES: SM declares that he has no competing interests.